SEC Form DEF 14A filed by Doximity Inc.

7/18/24 11:47:39 AM ET

$DOCS

EDP Services

Technology

Get the next $DOCS alert in real time by email

docs-20240717

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:


☐			Preliminary Proxy Statement

☐			Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☒			Definitive Proxy Statement

☐			Definitive Additional Materials

☐			Soliciting Material under §240.14a-12

Doximity, Inc.


(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):


☒			No fee required.

☐			Fee paid previously with preliminary materials

☐			Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

Doximity, Inc.

500 3rd St., Suite 510

San Francisco, CA 94107

July 18, 2024

Dear Doximity Stockholder:

We are pleased to invite you to attend the Annual Meeting of Stockholders (the “Annual Meeting”) of Doximity, Inc. (“Doximity”) for fiscal year 2024, to be held on August 29, 2024 at 9:00 a.m. Pacific Time. The Annual Meeting will be held virtually via a live audio-only webcast on the internet at http://www.virtualshareholdermeeting.com/DOCS2024. As described in the Notice, there are several ways to submit your vote until August 28, 2024 at 11:59 p.m. Eastern Time, and you can also vote during the meeting in accordance with the instructions provided in the Notice.

Details regarding the meeting and the business to be conducted are more fully described in the accompanying Notice of Annual Meeting and Proxy Statement for fiscal year 2024. You are entitled to vote at our Annual Meeting and any adjournments, continuations or postponements of our Annual Meeting only if you were a stockholder as of the close of business on July 5, 2024.

Thank you for your ongoing support of Doximity.

Sincerely,

Jeff Tangney

Chief Executive Officer, Director and Co-Founder

INFORMATION REGARDING YOUR VOTE

On or about July 18, 2024, we expect to mail to our stockholders a Notice of Internet Availability of Proxy Materials (the “Notice”) containing instructions on how to access our proxy statement for our Annual Meeting of Stockholders (the “Proxy Statement”) and our 2024 Annual Report on Form 10-K (“2024 Annual Report”). The Notice provides instructions on how to vote online or by telephone and includes instructions on how to receive a paper copy of proxy materials by mail. This Proxy Statement and our 2024 Annual Report can be accessed directly at the internet address www.proxyvote.com using the control number located on your proxy card. A copy of our 2024 Annual Report and our Proxy Statement are also available on our investor relations website at https://investors.doximity.com/overview/default.aspx.

Whether or not you plan to attend the meeting, please ensure that your shares are voted at the Annual Meeting by signing and returning a proxy card or by using our internet or telephonic voting system.

Doximity, Inc.

500 3rd St., Suite 510

San Francisco, CA 94107

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 29, 2024

Notice is hereby given that Doximity, Inc. will hold its Annual Meeting of Stockholders (the “Annual Meeting”) for fiscal year 2024 on August 29, 2024 at 9:00 a.m. Pacific Time via a live audio-only webcast on the internet at http://www.virtualshareholdermeeting.com/DOCS2024. As described herein, there are several ways to submit your vote until August 28, 2024 at 11:59 p.m. Eastern Time, and you can also vote during the meeting in accordance with the instructions provided herein.

We are holding the Annual Meeting for the following purposes, which are more fully described in the accompanying proxy statement:

•To elect two Class III directors to hold office until the annual meeting of stockholders to be held in 2027 or until their successors are duly elected and qualified, subject to their earlier resignation or removal;

•To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending March 31, 2025;

•To approve, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers for the fiscal year ending March 31, 2024, as disclosed in the Proxy Statement (the “Say-on-Pay Proposal”); and

•To transact any other business that properly comes before the Annual Meeting (including adjournments, continuations, and postponements thereof).

Our board of directors recommends that you vote “FOR” the director nominees named in Proposal One, “FOR” the ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm as described in Proposal Two, and "FOR" the Say-on-Pay Proposal.

We have elected to provide electronic access to our Annual Meeting materials, which include the proxy statement for our Annual Meeting (the “Proxy Statement”) accompanying this notice, in lieu of mailing printed copies. On or about July 18, 2024, we expect to mail to our stockholders a Notice of Internet Availability of Proxy Materials (the “Notice”) containing instructions on how to access our Proxy Statement and our 2024 Annual Report on Form 10-K (“2024 Annual Report”). The Notice provides instructions on how to vote online or by telephone and includes instructions on how to receive a paper copy of the proxy materials by mail. Our Proxy Statement and our 2024 Annual Report can be accessed directly at the internet address www.proxyvote.com using the control number located on your proxy card.

Only stockholders of record at the close of business on July 5, 2024 (the “Record Date”) are entitled to notice of and to vote at the Annual Meeting as set forth in the Proxy Statement.

By Order of the Board of Directors,

Jennifer Chaloemtiarana

General Counsel and Corporate Secretary

San Francisco, California

July 18, 2024

DOXIMITY, INC.

ANNUAL MEETING OF STOCKHOLDERS

PROXY STATEMENT

TABLE OF CONTENTS


GENERAL INFORMATION			1

PROPOSAL ONE: ELECTION OF DIRECTORS			9

PROPOSAL TWO: RATIFICATION OF THE APPOINTMENT OF OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM			13

REPORT OF THE AUDIT COMMITTEE OF THE BOARD			15

EXECUTIVE OFFICERS			16

CORPORATE GOVERNANCE			17

EXECUTIVE COMPENSATION			27

COMPENSATION DISCUSSION AND ANALYSIS			27

REPORT OF THE COMPENSATION COMMITTEE			38

SUMMARY COMPENSATION INFORMATION			39

GRANTS OF PLAN-BASED AWARDS			40

OUTSTANDING EQUITY AWARDS AT YEAR-END			41

OPTIONS EXERCISED AND STOCK VESTED TABLE			42

POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL			42

CEO PAY RATIO			43

PAY VERSUS PERFORMANCE			45

EQUITY COMPENSATION PLAN INFORMATION			48

PROPOSAL THREE: ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS			49

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT			50

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS			53

ADDITIONAL INFORMATION			55

DOXIMITY, INC.

500 3rd St., Suite 510

San Francisco, CA 94107

PROXY STATEMENT

FOR THE ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD AUGUST 29, 2024

GENERAL INFORMATION

Our board of directors (our “board”) solicits your proxy on our behalf for the Annual Meeting of Stockholders (the “Annual Meeting”) for fiscal year 2024 and at any adjournment, continuation or postponement of the Annual Meeting for the purposes set forth in this proxy statement for our Annual Meeting of Stockholders (this “Proxy Statement”) and the accompanying Notice of Annual Meeting of Stockholders. The Annual Meeting will be held virtually via a live audio-only webcast on the internet on August 29, 2024 at 9:00 a.m. Pacific Time. On or about July 18, 2024, we expect to mail our stockholders a Notice of Internet Availability of Proxy Materials (the “Notice”) containing instructions on how to access this Proxy Statement and our 2024 Annual Report on Form 10-K (“2024 Annual Report”). If you held shares of our Class A common stock or Class B common stock at the close of business on July 5, 2024 you are invited to attend the meeting at http://www.virtualshareholdermeeting.com/DOCS2024 and vote on the proposals described in this Proxy Statement. As described in this Proxy Statement, there are several ways to submit your vote until August 28, 2024, at 11:59 p.m. Eastern Time, and you can also vote during the meeting in accordance with the instructions provided herein.

In this Proxy Statement the terms “Doximity,” “the Company,” “we,” “us” and “our” refer to Doximity, Inc. and its subsidiaries. The mailing address of our principal executive offices is Doximity, Inc., 500 3rd St., Suite 510, San Francisco, CA 94107. The Company’s fiscal year ends on March 31st. Unless otherwise noted, all references to a particular year shall mean the Company’s fiscal year.


What matters are being voted on at the Annual Meeting?						You will be voting on: •The election of two Class III directors to serve until the annual meeting of stockholders to be held in 2027 or until their successors are duly elected and qualified; •A proposal to ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending March 31, 2025; •The approval, on a non-binding advisory basis, of the compensation paid to the Company’s named executive officers in fiscal 2024, as disclosed in this proxy statement (the “Say-on-Pay Proposal”); and •Any other business as may properly come before the Annual Meeting.

How does the board recommend that I vote on these proposals?						Our board recommends a vote: •“FOR” the election of Regina Benjamin, M.D., and Phoebe Yang as Class III directors; •“FOR” the ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending March 31, 2025; and •"FOR" for the non-binding, advisory Say-on-Pay Proposal.


Who is entitled to vote?						Holders of either class of our common stock at the close of business as of July 5, 2024, the record date for our Annual Meeting (the “Record Date”), may vote at the Annual Meeting. As of the Record Date, there were 125,132,035 shares of our Class A common stock and 60,496,570 shares of our Class B common stock outstanding. Our Class A common stock and Class B common stock will vote as a single class on all matters described in this Proxy Statement for which your vote is being solicited. Stockholders are not permitted to cumulate votes with respect to the election of directors. Each share of Class A common stock is entitled to one vote on each proposal and each share of Class B common stock is entitled to 10 votes on each proposal. Our Class A common stock and Class B common stock are sometimes collectively referred to in this Proxy Statement as our “common stock.” Registered Stockholders. If shares of our common stock are registered directly in your name with our transfer agent, American Stock Transfer & Trust Company, LLC (“AST”), you are considered the stockholder of record with respect to those shares. As the stockholder of record, you have the right to vote by internet during the meeting or vote through the internet, by telephone or, if you request or receive paper proxy materials by mail, by filling out and returning the proxy card. Throughout this Proxy Statement, we refer to these registered stockholders as “stockholders of record.” Street Name Stockholders. If shares of our common stock are held on your behalf in a brokerage account or by a bank or other nominee, you are considered to be the beneficial owner of shares that are held in “street name,” and the Notice was forwarded to you by your broker or nominee, who is considered the stockholder of record with respect to those shares. As the beneficial owner, you have the right to direct your broker, bank or other nominee as to how to vote your shares if you follow the instructions you receive from your broker, bank or nominee. You can also choose to vote your shares before the Annual Meeting by internet or telephone or by internet during the Annual Meeting, in each case by using the 16-digit control number, which is in the instructions accompanying your proxy materials, if your broker, bank or nominee makes those instructions available. Beneficial owners are also invited to attend the Annual Meeting.

What do I need to be able to attend the Annual Meeting online?						We will be hosting our Annual Meeting via live audio-only webcast. Any stockholder can attend the Annual Meeting live online at http://www.virtualshareholdermeeting.com/DOCS2024. The webcast (and your opportunity to vote online, if you did not submit your vote in advance or if you wish to change your vote) will start promptly at 9:00 a.m. Pacific Time on August 29, 2024. We encourage you to access the meeting prior to the start time. Online check-in will begin at 8:45 a.m. Pacific Time and you should allow sufficient time for the check-in procedures. Stockholders may vote while attending the Annual Meeting online, although we urge you to vote before the meeting using this proxy for efficiency of administration. In order to be able to attend the Annual Meeting, you will need the 16-digit control number, which is located on your proxy card. Instructions on how to participate in the Annual Meeting are also posted online at www.proxyvote.com.

What if I have technical difficulties or trouble accessing the Annual Meeting?						If you encounter any technical difficulties with accessing the audio-only webcast during the check-in or meeting time, please call the technical support number that will be posted on the Annual Meeting log-in page.


How many votes are needed for the approval of each proposal?						Proposal One. Directors shall be elected by a plurality of the voting power of the shares of our common stock present in person or by proxy at the Annual Meeting and entitled to vote on the election of directors. “Plurality” means that the nominees who receive the largest number of votes cast “For” such nominees are elected as directors. You may vote “For” or “Withhold” your vote for each of the nominees in the election of directors. Votes withheld and broker non-votes will have no effect on the outcome of the election of directors. Proposal Two. The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our year ending March 31, 2025 requires the affirmative vote of a majority of the voting power of the shares of our common stock present in person or by proxy at the Annual Meeting and entitled to vote on Proposal Two. Abstentions will have the same effect as a vote “Against” this proposal. Broker non-votes, if any, will have no effect on the outcome of the vote on this proposal. Proposal Three. Approval of the non-binding, advisory Say-on-Pay Proposal requires the affirmative vote of a majority of the voting power of the shares of our common stock present in person or by proxy at the Annual Meeting and entitled to vote on Proposal Three. Abstentions will have the effect of a vote “Against” this proposal. Broker non-votes will have no effect on the outcome of the vote on this proposal. As an advisory vote, this proposal is not binding on the Company, our Board or our Compensation Committee and it will not affect, limit, or augment any existing compensation or awards. Notwithstanding the advisory nature of this vote, our Board values the opinions expressed by our stockholders in their vote on this proposal, and will consider the outcome of the vote when making future compensation decisions for our named executive officers.

What is the quorum requirement?						A quorum is the minimum number of shares required to be present at the Annual Meeting to properly hold an annual meeting of stockholders and conduct business under our bylaws and Delaware law. The presence, in person or by proxy, of a majority of the voting power of all issued and outstanding shares of our common stock entitled to vote at the meeting will constitute a quorum at the Annual Meeting. Abstentions, withheld votes and broker non-votes are counted as shares present and entitled to vote at the meeting for the purposes of determining a quorum.


How do I vote?						If you are a stockholder of record, there are four ways to vote: (1)by internet at proxyvote.com 24 hours a day, seven days a week, until 11:59 p.m. Eastern Time on August 28, 2024 (have your Notice and proxy card in hand when you visit the website); (2)by toll-free telephone at 1-800-690-6903, until 11:59 p.m. Eastern Time on August 28, 2024 (have your Notice and proxy card in hand when you call); (3)by marking, signing, and dating your proxy card and mailing it to Doximity, Inc. c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717 (if you received printed proxy materials). Your proxy card must be received at the above location before 11:59 p.m. Eastern Time on August 28, 2024; or (4)by internet during the Annual Meeting. Instructions on how to attend and vote at the Annual Meeting are described at proxyvote.com. In order to be counted, proxies submitted by telephone or internet must be received by 11:59 p.m. Eastern Time on August 28, 2024. Proxies submitted by U.S. mail must be received before the start of the Annual Meeting. If you are a street name stockholder, please follow the instructions from your broker, bank or other nominee to vote by internet, telephone or mail before the meeting, or by internet during the Annual Meeting, in each case by using the 16-digit control number, which is in the instructions accompanying your proxy materials, if your broker, bank or nominee makes those instructions available.

Can I change my vote?						Yes. If you are a stockholder of record, you can change your vote or revoke your proxy by: •notifying our Corporate Secretary, in writing, at Doximity, Inc., 500 3rd St., Suite 510, San Francisco, CA 94107. Such notice must be received at the above location before 11:59 p.m. Eastern Time on August 28, 2024; •voting again using the telephone or internet before 11:59 p.m. Eastern Time on August 28, 2024 (your latest telephone or internet proxy is the one that will be counted); or •attending and voting during the Annual Meeting. Simply logging into the Annual Meeting will not, by itself, revoke your proxy. If you are a street name stockholder, you may revoke any prior voting instructions by contacting your broker, bank or other nominee or by attending the Annual Meeting and voting by internet during the meeting by using the 16-digit control number, which is in the instructions accompanying your proxy materials, if your broker, bank or nominee makes those instructions available.

What is the effect of giving a proxy?						Proxies are solicited by and on behalf of our board. Jeffrey Tangney, Anna Bryson and Jennifer Chaloemtiarana have been designated as proxy holders by our board. When proxies are properly granted, the shares represented by such proxies will be voted at the Annual Meeting in accordance with the instructions of the stockholder. If no specific instructions are given, however, the shares will be voted in accordance with the recommendations of our board as described above. If any matters not described in this Proxy Statement are properly presented at the Annual Meeting, the proxy holders will use their own judgment to determine how to vote the shares. If the Annual Meeting is adjourned, continued or postponed, the proxy holders can vote the shares on the new Annual Meeting date as well, unless you have properly revoked your proxy instructions, as described above.



What is the effect of votes withheld, abstentions and broker non-votes?						Votes withheld from any nominee, abstentions and “broker non-votes” (i.e., where a broker has not received voting instructions from the beneficial owner and for which the broker does not have discretionary power to vote on a particular matter) are counted as present for purposes of determining the presence of a quorum. Shares voting “withheld” have no effect on the election of directors. Abstentions have the same effect as a vote “against” the ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending March 31, 2025 and the non-binding, advisory Say-on-Pay Proposal. Broker non-votes will each have no effect on the outcome of any of our proposals in the Proxy Statement. Brokerage firms and other intermediaries holding shares of our common stock in street name for their customers are generally required to vote such shares in the manner directed by their customers. In the absence of timely directions, your broker will have discretion to vote your shares on our sole “routine” matter, the proposal to ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our year ending March 31, 2025. Absent direction from you, your broker will not have discretion to vote on Proposal One (election of directors) and Proposal Three (Say-on-Pay), which are “non-routine” matters.

Why did I receive a Notice of Internet Availability of Proxy Materials instead of a full set of proxy materials?						In accordance with the rules of the U.S. Securities and Exchange Commission (the “SEC”), we have elected to furnish our proxy materials, including this Proxy Statement and our 2024 Annual Report, primarily via the internet. On or about July 18, 2024, we mailed to our stockholders a Notice that contains instructions on how to access our proxy materials on the internet, how to vote at the meeting and how to request printed copies of the proxy materials and our 2024 Annual Report. Stockholders may request to receive all future proxy materials in printed form by mail or electronically by e-mail by following the instructions contained in the Notice. We encourage stockholders to take advantage of the availability of the proxy materials on the internet to help reduce the environmental impact of our annual meetings of stockholders.

Where can I find the voting results of the Annual Meeting?						We will announce preliminary results at the Annual Meeting. We will also disclose final results by filing a Current Report on Form 8-K within four business days after the Annual Meeting. If final results are not available at that time, we will provide preliminary voting results in the Current Report on Form 8-K and will provide the final results in an amendment to the Current Report on Form 8-K as soon as they become available.

How are proxies solicited for the Annual Meeting?						Our board is soliciting proxies for use at the Annual Meeting. All expenses associated with this solicitation will be borne by us. We will reimburse brokers or other nominees for reasonable expenses that they incur in sending our proxy materials to you if a broker, bank or other nominee holds shares of our common stock on your behalf. In addition, our directors and employees may also solicit proxies in person, by telephone or by other means of communication. Our directors and employees will not be paid any additional compensation for soliciting proxies.


I share an address with another stockholder, and we received only one paper copy of the proxy materials. How may I obtain an additional copy of the proxy materials?						We have adopted a procedure called “householding,” which the SEC has approved. Under this procedure, we deliver a single copy of the Notice and, if applicable, our proxy materials to multiple stockholders who share the same address, unless we have received contrary instructions from one or more of such stockholders. This procedure reduces our printing costs, mailing costs and fees. Stockholders who participate in householding will continue to be able to access and receive separate proxy cards. Upon written or oral request, we will deliver promptly a separate copy of the Notice and, if applicable, our proxy materials to any stockholder at a shared address to which we delivered a single copy of any of these materials. To receive a separate copy, or, if a stockholder is receiving multiple copies, to request that we only send a single copy of the Notice and, if applicable, our proxy materials, such stockholder may contact us at: Doximity, Inc. Attention: Corporate Secretary 500 3rd St., Suite 510 San Francisco, CA 94107 Street name stockholders may contact their broker, bank or other nominee to request information about householding.


What is the deadline to propose actions for consideration at next year’s annual meeting of stockholders or to nominate individuals to serve as directors?						Stockholder Proposals Stockholders may present proper proposals for inclusion in our proxy statement under Rule 14a-8 of the Securities Exchange Act of 1934 and for consideration at next year’s annual meeting of stockholders by submitting their proposals in writing to our Corporate Secretary in a timely manner. For a stockholder proposal to be considered for inclusion in our proxy statement for next year’s Annual Meeting, our Corporate Secretary must receive the written proposal at our principal executive offices not later than March 20, 2025. In addition, stockholder proposals must comply with the requirements of Rule 14a-8 regarding the inclusion of stockholder proposals in company-sponsored proxy materials. Stockholder proposals should be addressed to: Doximity, Inc. Attention: Corporate Secretary 500 3rd St., Suite 510 San Francisco, CA 94107 Our bylaws also establish an advance notice procedure for stockholders who wish to present a proposal before an annual meeting of stockholders but do not intend for the proposal to be included in our proxy statement. Our bylaws provide that the only business that may be conducted at an annual meeting of stockholders is business that is (i) specified in our proxy materials with respect to such annual meeting, (ii) otherwise properly brought before such annual meeting by or at the direction of our board or (iii) properly brought before such meeting by a stockholder of record entitled to vote at such annual meeting who has delivered timely written notice to our Corporate Secretary, which notice must contain the information specified in our bylaws. To be timely for the annual meeting of stockholders to be held in 2024, our Corporate Secretary must receive the written notice at our principal executive offices: •not earlier than March 20, 2025; and •not later than the close of business on April 19, 2025 In the event we hold the such annual meeting of stockholders more than 30 days before or more than 60 days after the one-year anniversary of the Annual Meeting, then, for notice by the stockholder to be timely, it must be received by the Corporate Secretary not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting, or the tenth day following the day on which public announcement of the date of such annual meeting is first made. If a stockholder who has notified us of an intention to present a proposal at an annual meeting of stockholders does not appear to present such proposal at such annual meeting, we are not required to present the proposal for a vote at such annual meeting. Nomination of Director Candidates Holders of our common stock may propose director candidates for consideration by our nominating and governance committee. Any such recommendations must include the nominee’s name and qualifications for membership on our board and be directed to our Corporate Secretary at the address set forth above. For additional information regarding stockholder recommendations for director candidates, see the section titled “Corporate Governance.”


						In addition, our bylaws permit stockholders to nominate directors for election at an annual meeting of stockholders. To nominate a director, a stockholder must provide the information required by our bylaws. In addition, the stockholder must give timely notice to our Corporate Secretary in accordance with our bylaws, which, in general, require that the notice be received by our Corporate Secretary within the time periods described above under the section titled “Stockholder Proposals” for stockholder proposals that are not intended to be included in a proxy statement. Additionally, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company's nominees must provide notice that sets forth the information required by Rule 14a-19 under the Securities Exchange Act of 1934 no later than June 30, 2025. Availability of Bylaws A copy of our bylaws is available via the SEC’s website at www.sec.gov. You may also contact our Corporate Secretary at the address set forth above for a copy of the relevant bylaw provisions regarding the requirements for making stockholder proposals and nominating director candidates.

Why is this Annual Meeting being held virtually?						We are hosting this meeting virtually at http://www.virtualshareholdermeeting.com/DOCS2024 in order to provide ease of access, real-time communication and cost savings for our stockholders and our Company. Hosting a virtual meeting provides easy access for our stockholders and facilitates participation since stockholders can participate from any location around the world.

PROPOSAL ONE:

ELECTION OF DIRECTORS

Number of Directors; Board Structure

Our board is divided into three staggered classes of directors. One class is elected each year at the annual meeting of stockholders for a term of three years. The term of the Class III directors expires at the Annual Meeting. The term of the Class I directors expires at the annual meeting to be held in 2025 and the term of the Class II directors expires at the annual meeting to be held in 2026. After the initial terms expire, directors are expected to be elected to hold office for a subsequent three-year term or until the election and qualification of their successors in office.

Nominees

Our board has nominated Dr. Regina Benjamin and Ms. Phoebe Yang for re-election as Class III directors to hold office until the annual meeting of stockholders to be held in 2027 or until their successors are duly elected and qualified, subject to their earlier resignation or removal. Each of the nominees is a current Class III director and member of our board and has consented to serve if elected.

Unless you direct otherwise through your proxy voting instructions, the persons named as proxies will vote all proxies received “FOR” the election of each nominee. If any nominee is unable or unwilling to serve at the time of the Annual Meeting, the persons named as proxies may vote for a substitute nominee chosen by our present board. In the alternative, the proxies may vote only for the remaining nominees, leaving a vacancy on our board. Our board may fill such vacancy at a later date or reduce the size of our board. We have no reason to believe that any of the nominees will be unwilling or unable to serve if elected as a director.

Vote Required

Directors shall be elected by a plurality of the voting power of the shares of our common stock, present in person or represented by proxy, at the Annual Meeting and entitled to vote on the election of directors. You may vote “For” or “Withhold” your vote for the nominees in the election of directors. Votes withheld and broker non-votes will have no effect on the outcome of the election of directors.

Recommendation of our Board

OUR BOARD RECOMMENDS THAT YOU VOTE “FOR” THE ELECTION OF EACH OF THE NOMINEES.

The biographies of each of the nominees and continuing directors below contain information regarding each such person’s service as a director, business experience, director positions held currently or at any time during the last five years, and the experiences, qualifications, attributes or skills that caused our board to determine that the person should serve as a director of the Company. In addition to the information presented below regarding each nominee’s and continuing director’s specific experience, qualifications, attributes and skills that led our board to the conclusion that he or she should serve as a director, we also believe that each of our directors has a reputation for integrity, honesty and adherence to high ethical standards. Each of our directors has demonstrated business acumen and an ability to exercise sound judgment, as well as a commitment of service to our Company and our board. Finally, we value our directors’ diversity and experience in relevant areas of business management and on other boards and board committees.

Our corporate governance guidelines also dictate that a majority of our board be comprised of directors whom our board has determined are “independent” directors under the published listing requirements of the New York Stock Exchange (“NYSE”).

Directors

The following table sets forth information regarding our directors, including their ages, as of July 1, 2024:

Name

Age

Positions and Offices Held with the Company

Class

Employee Directors:

Jeffrey Tangney

Chief Executive Officer and Director

Non-Employee Directors:

Kevin Spain (1)(2)

Director

Phoebe L. Yang (2)(3)

Director

III

Regina Benjamin (1)(3)

Director

III

Kira Wampler (2)(3)

Director

Timothy Cabral (1)

Director

____________

(1)Member of the audit committee.

(2)Member of the compensation committee.

(3)Member of the nominating and governance committee.

Class III Director Nominees

Regina Benjamin, M.D. Dr. Benjamin has served as a member of our board since September 2020. Dr. Benjamin is currently the founder and chief executive officer of, and is a practicing physician at, BayouClinic, Inc., since January 1990. Dr. Benjamin was appointed as the 18th United States Surgeon General by President Barack Obama in July 2009 and served in that role from November 2009 to August 2013. In addition, Dr. Benjamin has approximately 30 years of experience as a practicing family physician. Dr. Benjamin has served as the founder and chief executive officer of the BayouClinic/Gulf States Health Policy Center since 1990, and as the NOLA.com/Times Picayune Endowed Chair in Public Health Sciences at Xavier University of Louisiana since September 2013. Dr. Benjamin served as a member of the boards of directors of each of the Oak Street Health, Inc., a public healthcare services company, from October 2020 to May 2023, Ascension Health Alliance, a private healthcare company, from June 2014 to June 2023, TruBridge, Inc. (formerly known as Computer Programs and Systems, Inc.), a public technology company, since November 2017, and Kaiser Foundation Hospitals and Health Plan since June 2015. Dr. Benjamin also serves on the advisory board of HealthQuest Capital, a private growth capital firm, since May 2020. Dr. Benjamin served on the board of directors of Alere Inc., a public medical device company, from December 2013 to July 2015, as a member of the March of Dimes Board of Trustees from June 2014 to June 2019, Diplomat Pharmacy, Inc., a public company providing specialty pharmacy services, prior to its acquisition by OptimRx, April 2017 to 2015, and as a member of ConvaTec Group plc, a public medical products and technologies company, from August 2017 to May 2022. Dr. Benjamin holds a B.S. in Chemistry from Xavier University of Louisiana, an M.D. from the University of Alabama at Birmingham, and an M.B.A from Tulane University.

We believe Dr. Benjamin is qualified to serve on our board of directors because of her extensive experience in both business and practice as a medical doctor and her experience advising other public companies.

Phoebe L. Yang. Ms. Yang has served as a member of our board of directors since August 2022. Ms. Yang currently serves on the board of directors of each of GE Healthcare Technologies, Inc., a leading global S&P 500 medical technology and solutions company, since January 2023, and CommonSpirit Health, one of the largest U.S. tax-exempt health systems, since July 2020. From May 2020 to September 2022, Ms. Yang served as General Manager, Amazon Web Services, Healthcare, where she led Amazon’s cloud business focused on enabling healthcare enterprises with advanced cloud technologies. From 2013 to 2018, Ms. Yang served as Chief Strategy Officer and Chief Architect for Population Health at Ascension Health, one of the largest U.S. tax-exempt health systems. Ms. Yang holds a B.A. from the University of Virginia, and a J.D. from Stanford Law School, where she was President of the Stanford Law Review.

We believe Ms. Yang is qualified to serve on our board of directors because of her extensive industry experience as both a director and executive.

Continuing Members of the Board of Directors

Jeffrey Tangney. Mr. Tangney is our co-founder and has served as our Chief Executive Officer and as a member of our board of directors since our inception in April 2010. Mr. Tangney co-founded Epocrates, Inc., a mobile medical reference app company, in June 1999, and held various management positions at Epocrates through March 2010, most recently as its president and chief operating officer, as well as executive vice president of sales and marketing, since September 2005. From June 1993 to August 1997, Mr. Tangney served as a manager of ZS Associates, a consulting firm. Mr. Tangney holds a B.S. in Economics and Math from the University of Wisconsin-Madison and an M.B.A. from the Stanford Graduate School of Business.

We believe Mr. Tangney is qualified to serve as a member of our board of directors because of the perspective and experience he brings as our Chief Executive Officer.

Timothy Cabral. Mr. Cabral has served as a member of our board of directors since September 2020. From February 2010 to September 2020, Mr. Cabral served as chief financial officer for Veeva Systems Inc., (“Veeva”), a public cloud-computing company, during which time the company launched its initial public offering. In April 2024, he returned as interim chief financial officer of Veeva. From February 2008 to February 2010, Mr. Cabral served as chief financial officer and chief operations officer for Modus Group, LLC, a private a wireless solutions and services company, and served as chief financial officer and vice president of operations for Agistics, Inc., a private employee management services company, from March 2005 to June 2007. Prior to its acquisition by Oracle Corporation, Mr. Cabral spent more than seven years at PeopleSoft, Inc., a computer technology company, beginning in November 1997, where he held various positions, including vice president of products & technology finance from June 1999 to January 2005 and senior director of corporate financial planning and analysis from November 1997 to June 1999. Mr. Cabral has served on the board of directors of ServiceTitan, Inc. a private cloud-based home services company, since December 2019, on the board of directors of Veeva since January 2022, and on the board of Singlestore, Inc. a cloud database company, since March 2021. Mr. Cabral previously served on the board of directors of Apttus Corporation, a private software provider, from October 2017 to October 2018, when it was acquired by Thoma Bravo. Mr. Cabral holds a B.S. in Finance from Santa Clara University and an M.B.A. from the Leavey School of Business at Santa Clara University.

We believe Mr. Cabral is qualified to serve on our board of directors because of his experience as an executive and director of a public company.

Kevin Spain. Mr. Spain has served as a member of our board of directors since March 2011. Since March 2011, Mr. Spain has served as general partner of Emergence Capital Partners, a venture capital firm, and served as a principal of Emergence Capital Partners from September 2006 to March 2011. Prior to joining Emergence Capital Partners, Mr. Spain was a member of the corporate development group of Microsoft Corporation, a computer software company, from June 2003 to May 2006, and a member of the corporate development group of Electronic Arts Inc., a game software content and services company, from September 2000 to May 2003. Mr. Spain was previously co-founder and chief executive officer of Madison.com, Inc., which provided a hosted marketing management solution for small and medium sized companies. Mr. Spain served on the board of directors of Veeva Systems Inc., a public cloud-computing company, from May 2008 to July 2014. Mr. Spain currently serves on the board of directors of several privately held companies. Mr. Spain holds a B.A. in Business Administration from the University of Texas at Austin and an M.B.A. from The Wharton School of the University of Pennsylvania.

We believe Mr. Spain is qualified to serve on our board of directors because of his extensive industry experience and his experience advising other public companies.

Kira Wampler. Ms. Wampler has served as a member of our board of directors since March 2020. Ms. Wampler has served as venture chair of Redesign Health Inc., a private investment firm and healthcare innovation platform, since February 2020. From November 2016 to March 2019, Ms. Wampler served as the chief executive officer of Art.com Inc., a private art retailer company, during which time she led the company through its acquisition by Walmart Inc. From December 2014 to November 2016, Ms. Wampler served as the chief marketing officer of Lyft, Inc., a mobile ride-sharing app. Ms. Wampler also previously served as chief marketing officer of Trulia, Inc., a private real estate listing company, from November 2013 to November 2014. Ms. Wampler has served on the boards of directors of private companies including Candid Care Co. from September 2019 to January 2023, Personal Capital Corporation from March 2019 to August 2020, and Healthline Media, Inc. from March 2019 to August 2019. Ms. Wampler holds a B.S. in Foreign Services from Georgetown University School of Foreign Services, where she majored in History and Diplomacy, and an M.B.A. from the Fuqua School of Business at Duke University.

We believe Ms. Wampler is qualified to serve on our board of directors because of her extensive experience advising technology companies as both a director and executive.

PROPOSAL TWO:

RATIFICATION OF THE APPOINTMENT OF

OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Our audit committee has appointed Deloitte & Touche LLP ("Deloitte") as our independent registered public accounting firm to perform the audit of our consolidated financial statements for the year ending March 31, 2025, and we are asking you and other stockholders to ratify this appointment. During fiscal 2024, Deloitte served as our independent registered public accounting firm.

Although ratification of the appointment of Deloitte is not required by our bylaws or otherwise, our board is submitting the appointment of Deloitte to stockholders for ratification as a matter of good corporate governance. A majority of the votes properly cast is required in order to ratify the appointment of Deloitte. In the event that a majority of the votes properly cast do not ratify this appointment of Deloitte, our audit committee will reconsider whether or not to retain Deloitte. Even if the appointment is ratified, our audit committee, in its discretion, may direct the appointment of a different independent registered public accounting firm at any time during the year if they determine that such a change would be in the best interests of the stockholders.

We expect that representatives of Deloitte will attend the Annual Meeting, but given the audio-only nature of this Annual Meeting, they will not make a statement or respond to questions from stockholders at that time.

Audit Committee Charter and Practices on Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors

Our audit committee operates under the audit committee charter pursuant to which our audit committee must pre-approve all auditing services and non-audit services to be provided to the Company by independent auditors. Pursuant to the audit committee charter, the pre-approval requirement is waived for non-audit services if the “de minimis” provisions of Section 10A(i)(1)(B) of the Exchange Act apply. Further, our audit committee may delegate authority to pre-approve non-audit services to the audit committee chair up to a dollar amount agreed upon by our audit committee, who shall report all pre-approval decisions to our audit committee at its next scheduled meeting.

Audit Fees

The following table sets forth the fees billed or to be billed by Deloitte and its affiliates for professional services rendered with respect to the years ended March 31, 2024 and 2023. All of these services were approved by our audit committee.


Fee Category	2024		2023
Audit Fees (1)	$	2,618,901	$	2,432,707
Audit-Related Fees	—		—
Tax Fees	—		—
All Other Fees (2)	7,391		7,391
Total Fees	$	2,626,292	$	2,440,098

_____________

(1)Audit Fees consist of fees for professional services provided in connection with the audit of our consolidated financial statements, including reviews of our quarterly condensed consolidated financial statements, accounting consultations billed as audit services, and other regulatory filings.

(2)All Other Fees consist of aggregate fees billed for products and services provided by the independent registered public accounting firm other than those disclosed above. The other fees billed in both 2024 and 2023 were for the Company’s subscription to the Deloitte Accounting Research Tool, a web-based library of accounting and financial disclosure literature.

Vote Required

Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our year ending March 31, 2025 requires the affirmative vote of a majority of the voting power of the shares of our common stock, present in person or represented by proxy, at the Annual Meeting and entitled to vote on the proposal. Abstentions will have the same effect as a vote “Against” this proposal. Broker non-votes, if any, will have no effect on the outcome of the vote on this proposal.

Recommendation of our Board

OUR BOARD RECOMMENDS THAT YOU VOTE “FOR” RATIFICATION OF THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING MARCH 31, 2025.

REPORT OF THE AUDIT COMMITTEE OF THE BOARD

The information contained in this audit committee report shall not be deemed to be “soliciting material,” “filed” with the SEC, subject to Regulations 14A or 14C of the Exchange Act, or subject to the liabilities of Section 18 of the Exchange Act. No portion of this audit committee report shall be deemed to be incorporated by reference into any filing under the Securities Act, or the Exchange Act, through any general statement incorporating by reference in its entirety the proxy statement in which this report appears, except to the extent that Doximity specifically incorporates this report or a portion of it by reference. In addition, this report shall not be deemed filed under either the Securities Act or the Exchange Act.

This report is submitted by the audit committee of the board. The audit committee consists of the directors whose names appear below. None of the members of the audit committee is an officer or employee of Doximity, and the board has determined that each member of the audit committee is “independent” for audit committee purposes as that term is defined under Rule 10A-3 of the Exchange Act and the applicable NYSE rules. Each member of the audit committee meets the requirements for financial literacy under the applicable rules and regulations of the SEC and NYSE.

The audit committee’s general role is to assist the board in monitoring the Company’s financial reporting process and related matters. The audit committee’s specific responsibilities are set forth in its charter.

The audit committee has reviewed the Company’s consolidated financial statements for the year ended March 31, 2024 and met with its management team, as well as with representatives of Deloitte & Touche LLP, the Company’s independent registered public accounting firm, to discuss the consolidated financial statements. The audit committee also discussed with members of Deloitte & Touche LLP the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board.

In addition, the audit committee received the written disclosures and the letter from Deloitte & Touche LLP required by applicable requirements of the Public Company Accounting Oversight Board regarding the independent accountant’s communications with the audit committee concerning independence and discussed with members of Deloitte & Touche LLP its independence.

Based on these discussions, the financial statement review and other matters it deemed relevant, the audit committee recommended to the board that the Company’s audited consolidated financial statements for the year ended March 31, 2024 to be included in its fiscal 2024 Annual Report.

Audit Committee

Timothy Cabral (Chair)

Regina Benjamin

Kevin Spain

EXECUTIVE OFFICERS

The following table sets forth information regarding our executive officers for fiscal year 2024, including their ages as of July 1, 2024. Our executive officers are appointed by, and serve at the discretion of, our board and each holds office until a successor is duly elected and qualified or until such officer’s earlier resignation or removal. There are no family relationships among any of our directors or executive officers.

Name

Age

Positions

Jeffrey Tangney

Chief Executive Officer and Director

Anna Bryson

Chief Financial Officer

Craig Overpeck (1)

SVP, Commercial Operations

Nate Gross, M.D.

Chief Strategy Officer

Jennifer Chaloemtiarana

General Counsel

(1) The duties of Craig Overpeck were adjusted for fiscal year 2025, and while he still holds the title of SVP, Commercial Operations, he is no longer acting as an executive officer for the Company. Mr. Overpeck remains employed with the Company as an executive in its subsidiary, Curative Talent, LLC.

Information Concerning Executive Officers

In addition to Mr. Tangney, who serves as a director, our executive officers during fiscal year 2024 consisted of the following:

Anna Bryson. Ms. Bryson has served as our Chief Financial Officer since February 2021. From August 2017 to February 2021, Ms. Bryson served in various finance roles within our company, most recently as our VP of Strategic Finance, Financial Planning, and Analysis. Prior to joining our company, Ms. Bryson served as the founder and chief executive officer of ACB Capital, an investment advisory firm, from June 2012 to July 2017. Ms. Bryson holds both a B.A. and an M.A. in Philosophy, Politics, and Economics from the University of Oxford.

Craig Overpeck. Mr. Overpeck has served as our SVP of Commercial Operations since May 2023. While still holding that title, Mr. Overpeck’s duties were adjusted for fiscal year 2025 and he is no longer acting as an executive officer for the Company. Mr. Overpeck remains employed with the Company as an executive in its subsidiary, Curative Talent, LLC. Craig has over 25 years of experience delivering digital solutions that connect and serve physicians. Prior to joining Doximity in 2023, Craig served as the U.S. chief operating officer at M3 for over a decade and built MDLinx, which was acquired by M3 and became a critical part of the company’s U.S. business. During his tenure at M3, he built the largest global market research offering, M3 Global Research, which connected the company’s physician communities across Asia, Europe, and North America. He received his B.S. from Ursinus College.

Nate Gross, M.D. Dr. Gross is our co-founder and has served as our Chief Strategy Officer since February 2021, after serving as Vice President of Business Development and in various strategy, finance and product roles within our company since 2012, preceded by serving on contract since 2010 while finishing graduate school. Starting in 2011, he has served as co-founder and member of the board of directors of Rock Health, a digital health nonprofit. Dr. Gross holds a B.A. in Government from Claremont McKenna College, M.B.A from Harvard Business School and M.D. from the Emory University School of Medicine.

Jennifer Chaloemtiarana. Ms. Chaloemtiarana has served as our General Counsel since August 2020. From November 2019 to July 2020, she served as Chief Legal Officer and Corporate Secretary of Rodan & Fields, responsible for the legal and compliance functions, and prior to that, since 2014, served as General Counsel, Corporate Secretary and Chief Privacy Officer of Castlight Health, Inc., responsible for the legal, compliance and security functions. Ms. Chaloemtiarana holds a B.S. from Cornell University and a J.D. from the University of Michigan Law School, where she was a Contributing Editor of the Michigan Law Review.

CORPORATE GOVERNANCE

Our business and affairs are managed under the direction of our board, which is elected by our stockholders. In carrying out its responsibilities, our board selects and monitors our top management, provides oversight of our financial reporting processes, and determines and implements our corporate governance policies.

Our board and management team are committed to good corporate governance to ensure that we are managed for the long-term benefit of our stockholders, and we have a variety of policies and procedures to promote such goals. To that end, during the past year, our management periodically reviewed our corporate governance policies and practices to ensure that they remain consistent with the requirements of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), SEC rules and NYSE Listed Company Manual standards.

Besides verifying the independence of the members of our board and committees (which is discussed in the section titled “Independence of Our Board of Directors”), at the direction of our board, we also:

•Periodically review and make necessary changes to the charters for our audit, compensation, and nominating and governance committees;

•Establish disclosures control policies and procedures in accordance with the requirements of the Sarbanes-Oxley Act and the rules and regulations of the SEC;

•Have a procedure for receipt and treatment of anonymous and confidential complaints or concerns regarding audit or accounting matters in place; and

•Have a code of conduct that applies to our employees, officers and directors, including our chief executive officer, president, chief financial officer, and other executive and senior financial officers.

In addition, we have adopted a set of corporate governance guidelines. Our nominating and governance committee is responsible for reviewing our corporate governance guidelines from time to time and reporting and making recommendations to our board concerning corporate governance matters. A copy of our corporate governance guidelines can be found on our investor relations website at https://investors.doximity.com/governance/governance-documents/default.aspx. Our corporate governance guidelines address such matters as:

•Director Independence - Independent directors must constitute at least a majority of our board;

•Monitoring Board Effectiveness - Our board must conduct an annual self-evaluation of our board and its committees;

•Board Access to Independent Advisors - Our board as a whole, and each of its committees separately, have authority to retain independent experts, advisors or professionals as each deems necessary or appropriate; and

•Board Committees - All members of the audit, compensation, and nominating and governance committees are independent in accordance with applicable NYSE Listed Company Manual standards.

Independence of Our Board of Directors

As required under NYSE listing standards, a majority of the members of a listed company’s board of directors must qualify as “independent,” as affirmatively determined by the board of directors. The board of directors consults with the company’s counsel to ensure that the board’s determinations are consistent with relevant securities and other laws and regulations regarding the definition of “independent,” including those set forth in pertinent listing standards of the NYSE, as in effect from time to time.

Consistent with these considerations, after review of all relevant identified transactions or relationship between each director, or any of such director’s family members, and the Company, its senior management and its independent auditors, our board has affirmatively determined that the following five directors are independent directors within the meaning of the applicable NYSE listing standards: Mr. Spain, Ms. Yang, Dr. Benjamin, Ms. Wampler and Mr. Cabral. In making this determination, our board found that none of these directors or nominees had a material or other disqualifying relationship with the Company.

In making those independence determinations, our board took into account certain relationship and transactions that occurred in the ordinary course of business between the Company and entities with which some of its directors are or have

been affiliated. See the section titled “Certain Relationships and Related Party Transactions” for information about related party transactions involving members of our board or their affiliates.

Board Leadership Structure

The Company’s board is currently chaired by the Chief Executive Officer of the Company, Mr. Tangney.

The Company believes that combining the positions of Chief Executive Officer and chairperson helps to ensure that the Board and management act with a common purpose, providing a single, clear chain of command to execute the Company’s strategic initiatives and business plans. In addition, the Company believes that a combined Chief Executive Officer/chairperson is well positioned to act as a bridge between management and the Board, facilitating the regular flow of information. The Company also believes that it is advantageous to have a chairperson with an extensive history with and knowledge of the Company (as is the case with the Company’s Chief Executive Officer).

Our Board’s Role in Risk Oversight

Our board has responsibility for the oversight of our risk management processes and, either as a whole or through its committees, regularly discusses with management our major risk exposures, their potential impact on our business and the steps we take to manage them. The risk oversight process includes receiving regular reports from board committees and members of senior management to enable our board to understand our risk identification, risk management, and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory, cybersecurity, strategic, and reputational risk.

Our board believes that open communication between our management team and our board is essential to management and oversight. Our board meets with our Chief Executive Officer and other members of the senior management team at quarterly meetings of our board, as well as at such other times as they deem appropriate, where, among other topics, they discuss major risk exposures, their potential impact on our business and steps we take to manage them.

While our board is ultimately responsible for risk oversight, our board committees assist our board in fulfilling its oversight responsibilities in certain areas of risk. Our audit committee oversees and reviews the Company’s guidelines and policies that govern the process by which the Company’s exposure to risk is assessed and managed by management. More specifically, our audit committee assists our board in fulfilling its oversight responsibilities with respect to risk assessment and risk management in the areas of internal control over financial reporting, disclosure controls and procedures, legal and regulatory compliance, liquidity risk, enterprise risk management and cybersecurity. Our audit committee also discusses and considers with our management team and Deloitte & Touche LLP the Company's major financial, operational, privacy, security, competition, regulatory, enterprise, cybersecurity, and accounting risk exposures or other exposures and the steps that the Company's management has taken to monitor and control such exposures. Our nominating and governance committee assists our board in fulfilling its oversight responsibilities with respect to the management of risk associated with our board’s organization, membership, structure, corporate governance and environmental, social and governance initiatives. Our compensation committee assesses risks created by the incentives inherent in our compensation policies. Finally, our full board reviews strategic and operational risk in the context of reports from our management team, receives reports on all significant committee activities at each regular meeting and evaluates the risks inherent in significant transactions.

Meetings of Our Board

In fiscal 2024, our board held four meetings, and acted by unanimous written consent two times. Each director attended at least 75% of all meetings of our board and the committees on which he or she served that were held during fiscal 2024. Under our corporate governance guidelines, directors are expected to spend the time needed and meet as frequently as our board deems necessary or appropriate to discharge their responsibilities. Directors are also expected to make efforts to attend our annual meeting of stockholders, all meetings of our board and all meetings of the committees on which they serve.

Code of Conduct

Our board has adopted a code of conduct that applies to all of our employees, officers and directors, including our chief executive officer, chief financial officer, and other executive and senior financial officers. The full text of our code of conduct is available on our investor relations website at https://investors.doximity.com/governance/governance-documents/

default.aspx. We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding amendments to, or waiver from, a provision of our code of conduct by posting such information on the website address and location specified above. During fiscal 2024, no waivers were granted from any provision of the code of conduct.

Risks Related to Compensation Policies and Practices

As part of its oversight function, our board, and our compensation committee in particular, along with our management team, considers potential risks when reviewing and approving various compensation plans, policies and awards, and believes that our compensation plans, policies and awards, balance an appropriate risk and reward profile in relation to our overall business strategy and do not encourage our employees, including our executive officers, to engage in risk taking to a degree that is reasonably likely to have a materially adverse impact on us or our operations.

Committees of Our Board

Our board has established an audit committee, a compensation committee, and a nominating and governance committee. The composition and responsibilities of each of the committees of our board is described below. Members serve on these committees until their resignation or until as otherwise determined by our board. Each of the audit, compensation, and nominating and governance committees operates pursuant to a separate written charter adopted by our board that is available to stockholders at https://investors.doximity.com/governance/governance-documents/default.aspx.

Audit Committee

Our audit committee consists of Messrs. Cabral and Spain and Dr. Benjamin, with Mr. Cabral serving as Chair. The Board reviews the NYSE listing standards definition of independence for audit committee members on an annual basis and has determined that all members of the audit committee meet the requirements for independence under NYSE listing standards and SEC rules and regulations. Each member of our audit committee meets the financial literacy requirements of NYSE listing standards. In addition, our board has determined that Mr. Cabral is an audit committee financial expert within the meaning of Item 407(d) of Regulation S-K under the Securities Act of 1933 (the “Securities Act”). Our audit committee, among other things:

•selects a qualified firm to serve as the independent registered public accounting firm to audit our consolidated financial statements;

•helps to ensure the independence and performance of the independent registered public accounting firm;

•discusses the scope and results of the audit with the independent registered public accounting firm and reviews, with management and the independent registered public accounting firm, our interim and year-end results of operations;

•develops procedures for employees to submit concerns anonymously about questionable accounting or audit matters;

•reviews our policies on risk assessment and risk management;

•reviews related party transactions;

•obtains and reviews a report by the independent registered public accounting firm at least annually, that describes our internal control procedures, any material issues with such procedures and any steps taken to deal with such issues; and

•approves (or, as permitted, pre-approves) all audit and all permissible non-audit services, other than de minimis non-audit services, to be performed by the independent registered public accounting firm.

Our audit committee annually reviews the independent registered public accounting firm’s independence, including reviewing all relationships between the independent registered public accounting firm and us and any disclosed relationships or services that may impact the objectivity and independence of the independent registered public accounting firm, and the independent registered public accounting firm’s performance.

Our audit committee operates under a written charter that satisfies the applicable rules of the SEC and the listing standards of the NYSE. In fiscal 2024, our audit committee held five meetings, and acted by unanimous written consent one time.

Compensation Committee

Our compensation committee consists of Mses. Yang and Wampler and Mr. Spain, with Mr. Spain serving as Chair. All current members of the compensation committee meet the requirements for independence under NYSE listing standards and SEC rules and regulations. Each member of the compensation committee is also a non-employee director, as defined pursuant to Rule 16b-3 promulgated under the Exchange Act. The purpose of our compensation committee is to discharge the responsibilities of our board relating to compensation of our executive officers. Our compensation committee, among other things:

•reviews, or determines, or makes recommendations to our board regarding, the compensation of our Chief Executive Officer and all executive officers;

•administers our stock and equity incentive plans, and approves grants to our executive officers and directors;

•reviews and approves, or makes recommendations to our board regarding our compensation plans and programs;

•establishes and reviews general policies relating to compensation and benefits of our employees;

•oversees and at least annually reviews management's assessment of major compensation-related risk exposures and the mitigation thereof;

•periodically reviews our human capital strategies, initiatives, and programs with respect to our employee health, safety and well-being; engagement; pay equity; and diversity and inclusion;

•periodically reviews and recommends to our board the type and amount of compensation paid to directors; and

•considers the results of stockholder advisory votes on executive compensation and the frequency of such vote.

Our compensation committee operates under a written charter that satisfies the applicable rules of the SEC and the listing standards of the NYSE. In fiscal 2024, our compensation committee held five meetings and acted by unanimous written consent four times.

Compensation Committee Interlocks and Insider Participation

During fiscal 2024, Mses. Yang and Wampler and Mr. Spain served as members of the compensation committee. None of the members of our compensation committee is or has been an officer or employee of our Company or has had any other relationship requiring disclosure herein. None of our executive officers currently serves, or in the past year has served, as a member of the board or compensation committee of any entity that has one or more executive officers serving on our board or compensation committee. See the section titled “Certain Relationships and Related Party Transactions” for information about related party transactions involving members of our compensation committee or their affiliates.

Nominating and Governance Committee

Our nominating and governance committee consists of Mses. Yang and Wampler and Dr. Benjamin, with Ms. Wampler serving as Chair. All members of the nominating and governance committee meet the requirements for independence under NYSE listing standards and SEC rules and regulations. Our nominating and governance committee, among other things:

•identifies, evaluates and selects, or makes recommendations to our board regarding, nominees for election to our board and its committees;

•evaluates the performance of our board and of individual directors;

•considers and makes recommendations to our board regarding the composition of our board and its committees;

•reviews developments in corporate governance practices;

•evaluates the adequacy of our corporate governance practices and reporting; and

•develops and makes recommendations to our board regarding corporate governance guidelines and matters.

The nominating and governance committee operates under a written charter that satisfies the applicable listing requirements and rules of the NYSE. In fiscal 2024, our nominating and governance committee held two meetings.

Identifying and Evaluating Director Nominees

Our board has delegated to our nominating and governance committee the responsibility of identifying suitable candidates for nomination to our board (including candidates to fill any vacancies that may occur) and assessing their qualifications in light of the policies and principles in our corporate governance guidelines and the committee’s charter. Our nominating and governance committee may gather information about the candidates through interviews, detailed questionnaires, comprehensive background checks, or any other means that the committee deems to be appropriate in the evaluation process. Our nominating and governance committee then meets as a group to discuss and evaluate the qualities and skills of each candidate, both on an individual basis and taking into account the overall composition and needs of our board. Based on the results of the evaluation process, our nominating and governance committee recommends candidates for our board’s approval as director nominees for election to our board.

Minimum Qualifications

Our nominating and governance committee uses a variety of methods for identifying and evaluating director nominees and will consider all facts and circumstances that it deems appropriate or advisable. In its identification and evaluation of director candidates, our nominating and governance committee will consider the current size and composition of our board, as well as the needs of our board and the respective committees of our board. Some of the qualifications that our nominating and governance committee consider include, without limitation, issues of character, ethics, integrity, judgment, independence, diversity, skills, education, expertise, business acumen, length of service, understanding of our business and industry, and other commitments. Although our board does not maintain a specific policy with respect to board diversity, our board believes that our board should be a diverse body, and our nominating and governance committee considers a broad range of backgrounds and experiences.

Nominees must also have proven achievement and competence in their field, the ability to exercise sound business judgment, an objective perspective, the ability to offer advice and support to our management team, and the ability to make significant contributions to our success. Nominees must also have skills that are complementary to those of our existing board, the highest ethics, a commitment to the long-term interests of our stockholders, and an understanding of the fiduciary responsibilities that are required of a director. Nominees must have sufficient time available in the judgment of our nominating and governance committee to effectively perform all board and committee responsibilities. Members of our board are expected to prepare for, attend and participate in all meetings of our board and applicable committee meetings. Other than the foregoing, there are no stated minimum criteria for director nominees, although our nominating and governance committee may also consider such other factors as it may deem, from time to time, are in the company's and our stockholders’ best interests. After completing its review and evaluation of director candidates, our nominating and governance committee recommends to our full board the director nominees for selection.

Stockholder Recommendations

Eligible stockholders may submit recommendations for director candidates to our nominating and governance committee by sending the individual’s name and qualifications to our General Counsel at Doximity, Inc., 500 3rd St., Suite 510, San Francisco, CA 94107, who will forward all recommendations to our nominating and governance committee. Any such recommendations should include the information required by our bylaws. Our nominating and governance committee will evaluate any candidates properly recommended by stockholders against the same criteria and pursuant to the same policies and procedures applicable to the evaluation of candidates proposed by directors or members of our management team.

Stockholder and Interested Party Communications

Our board provides to every stockholder and interested party the ability to communicate with our board, as a whole, and with individual directors on our board through an established process for stockholder and interested party communication. A stockholder or interested party may send any communications directed to our board as a whole to our General Counsel at Doximity, Inc., 500 3rd St., Suite 510, San Francisco, CA 94107, or [email protected]. If communication is directed to an individual director in such capacity as a member of our board, such communication may be sent to the attention of the individual director, care of the General Counsel at the foregoing address.

Our General Counsel, in consultation with appropriate members of our board, as necessary, will review all incoming communications and, if appropriate, all such communications will be forwarded to the appropriate member or members of our board, or if none is specified, to the Chair of our board. The General Counsel will generally not forward

communications if they are deemed inappropriate, consist of individual grievances or other interests that are personal to the party submitting the communication and could not reasonably be construed to be of concern to securityholders or other constituencies of the Company, solicitations, advertisements, surveys, “junk” mail, or mass mailings.

Hedging Policy

Our Board of Directors has adopted an insider trading policy, which prohibits our Directors and employees (including our executive officers) from hedging or engaging in similar transactions designed to decrease the risks associated with holding our Class A common stock. In addition, our insider trading policy prohibits our Directors and employees (including our executive officers) from trading in derivative securities related to our Class A common stock, which include publicly traded call and put options, engaging in short selling of our Class A common stock, holding our Class A common stock in a margin account, and pledging our shares as collateral for a loan. In November 2023, the Audit Committee of our Board of Directors granted a one-time exception to the insider trading policy to enable Mr. Tangney to secure a loan with a third-party financial institution using certain shares of Doximity Class A common stock owned by him as collateral, which represented less than 5% of his overall equity ownership of the Company.

Clawback Policy

On October 26, 2023, our Compensation Committee adopted a Clawback Policy applicable to all of our current and former executive officers as defined under Rule 16a-1(f) under Section 16 of the Exchange Act. Under this policy, our Compensation Committee is obligated to recover erroneously awarded incentive-based compensation, if any, in the event we are required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws. This policy is intended to satisfy the requirements of Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act and any related rules or regulations promulgated by the SEC or the NYSE. In addition, commission amounts paid to our employees may be clawed back by the Company under certain circumstances such as de-booked sales activity or failure to follow Company policy. Our equity compensation plan also allows us to recover equity incentive compensation paid to our executive officers in connection with any right we may have under any Company clawback, forfeiture or recoupment policy in effect from time to time.

Environmental, Social and Governance Matters

At Doximity, we believe active management of environmental, social and governance (ESG) issues is fundamental to our mission of helping every physician be more productive so they can provide better care for their patients. By serving the needs of our members, our employees, our partners, and our planet, we can better serve the long term interests of our business and stakeholders.

Equitable, Accessible and High-Quality Healthcare, Conducted in a Secure Manner

At Doximity, we understand the challenges providers face every day, and we aim to bring the power of software to the healthcare industry. Our digital tools are built specifically for medicine and designed to make technology work for providers – not the other way around. Our team’s commitment to supporting better health outcomes is embedded across our product portfolio.

•Our newsfeed is carefully curated and personalized to our clinician members to help ensure timely access to practice-specific news, information and updates on the latest clinical research. By disseminating relevant information more rapidly, our newsfeed helps empower a large and decentralized health care workforce with important practice information. Through our newsfeed, we also strive to keep healthcare professionals apprised of health-related news in the lay press to help them anticipate and respond appropriately to patient questions and concerns.

•Our network tools were built to facilitate clinical collaboration at scale. By bringing medical professionals across the nation into a single virtual community, Doximity empowers providers to communicate and collaborate with other care providers across the boundaries of otherwise heavily siloed healthcare institutions. We believe this ultimately increases provider productivity and enables higher-quality, lower-friction patient care.

•Our careers tools help our members manage their careers from training through retirement. We have the ability to match providers with primary care and specialist jobs in areas of highest need — geographically isolated rural communities, under-resourced urban hospitals, and indigenous American reservations.

•Our comprehensive physician profiles allow us to intelligently match these opportunities to providers with known academic or professional ties to the associated communities, which furthers our aim of facilitating a more equitable distribution of health care resources.

•Our suite of communication and digital workflow tools available to members of our network are designed to make their daily workflows more efficient, all in a HIPAA-compliant environment. These tools include telehealth, digital fax and e-signature, secure messaging, AI writing assistant, and scheduling features, and each is built with a goal of streamlining the workflow of the medical professional so that they can provide better care for their patients.

◦Our telehealth tools help to improve provider productivity, remove barriers to equitable healthcare, and reduce emissions created by travel to in-person care. Doximity’s telehealth solution Dialer is designed to be easily accessible for a wide range of people regardless of their device, connectivity, or technical aptitude. Patients simply receive a text from their physician and opt into a secure, HIPAA-compliant call without the burden of cumbersome application installation or account registration. Our focus on accessibility goes hand-in-hand with our commitment to health equity, including addressing barriers to both in-person and virtual care. Some of the Dialer features we offer include non-English language support, access to live interpreter services, low-bandwidth detection and video optimization.

◦Our digital fax and e-signature tools serve as the information highway between medical providers and institutions. Not only does this help increase physician productivity, it also helps to reduce emissions and save trees by removing paper from the equation.

◦Our messaging functionality enables members to collaborate in a HIPAA-compliant manner regarding patient consultations and coordinate care across multiple care team members, specialists, systems, or locations.

◦Our HIPAA-compliant generative AI writing assistant, helps physicians and other medical professionals reclaim the time they spend on administrative writing tasks, such as drafting letters of patient support, insurance appeals, patient education materials, letters of recommendation, and even grant applications, and it integrates with our HIPAA-compliant digital fax to enable easy transmission of the final document.

◦Our scheduling tool Amion helps centralize clinical on-call schedules across medical teams, departments, and even institutions. This centralization helps enable more efficient provider-to-provider collaboration and more timely access to on-call specialists. By helping providers quickly answer the question “am I on,” Amion helps eliminate confusion and streamline communication and clinical workflow. With Amion, clinical teams can build and maintain more equitable schedules and sync work shifts to personal calendars. The tool combines scheduling with communication and enables team members to submit special requests and swap shifts.

We do all of this in a manner consistent with current industry standards for data security. The privacy of our members and their work is paramount. Members are provided with options designed to allow them to control their data, and they can request deletion of their data under applicable privacy laws and procedures. We also do not share our members’ email or private/back office line with anyone beyond the colleagues that they expressly choose.

Physician information that is posted to profiles is protected with anti-scraping technologies such as a Web Application Firewall, Runtime Application Self-Protection, Bot Protection, Rate-Limiting, and our network employs DDoS mitigation technology to protect against attacks. All data is encrypted in transit and at rest using TLS 1.2, and personal health information is encrypted at rest using AES-256 encryption. Along with a dedicated in-house security team and contracted security researchers, we maintain a comprehensive bug bounty program for proactive vulnerability inspection of our entire offering.

In addition, our communications solutions are HIPAA-compliant, providing medical professionals with a critical platform for protected communications. All Doximity employees, as well as contractors who work on our systems that facilitate healthcare communications, are required to complete HIPAA Privacy and Security along with a Data Privacy and Cyber Security training.

Our People

Driven by our mission to connect healthcare professionals and make their lives more productive, Doximity is guided by our core values to create a culture focused on solving problems (“Get Stuff Done”), innovating (“Stretch Goals”),

allowing all voices to be heard (“Straight Talk”), and embracing each employee’s unique attributes (“Bring the Real You”). To engage our employees, we leverage townhalls, offsites, surveys and other channels. We help employees to continue developing their knowledge, skills and careers through training, mentorships, and professional development opportunities, and a performance management process focused on growth career advancement, regular check-ins and continuous feedback. We value the interconnections between physical, mental and financial wellbeing. We seek to support our employees holistically through our compensation and benefits so they can put their best foot forward each day.

Employees are provided with market competitive salaries, equity stock incentives, an employee stock purchase plan, bonus opportunities, and a 401(k) with employer match. In addition to high quality medical and dental benefits, we provide family planning benefits and a monthly well-being stipend. We strongly believe in a work-life balance at Doximity, providing flexible working arrangements to accommodate individual and family needs, and encouraging employees to enjoy life outside of work.

Diversity, Equity, Inclusion and Belonging

Diversity, equity, inclusion and belonging (DEIB) efforts at Doximity focus on our employees, members and community. Our programs seek to increase diverse representation, equity, awareness, and cultural humility. Doximity team members are committed to working towards a more equitable world both within and beyond our office walls. This starts by fostering an inclusive and diverse work environment where differences are valued and all employees are encouraged to bring their full, authentic selves to work daily. We also promote a culture of "straight talk" where we expect everyone to say what they mean and, in return, listen to all opinions with an open mind. We believe creating inclusive cultures requires an equitable and inclusive approach across people, policies, and products. As a health tech company and professional medical network, this understanding helps us to advance digital health equity and access, amplify and ensure underrepresented voices are heard, and create opportunities for underrepresented people in both medicine and technology.

For our employees, we have DEIB programs that focus on i) developing a diverse candidate pool through expanded job boards and recruiting events, and partnering with tech community affinity groups, ii) actively engaging with employees on DEIB issues throughout the year through open Slack channels and all-hands conversations and through formal demographic reviews and reports on a biannual basis; iii) training and development through hiring manager training, workshops, and a DEI specific resource platform, and iv) employee resource groups for women, LGBTQ+, BIPOC and support for other identity groups.

Environmental Policy

Doximity is committed to being a responsible steward of the environment by monitoring our environmental impact and complying with all relevant laws and regulations. Our products are offered through a cloud-based platform and do not require proprietary hardware. Additionally, we continue to lower our environmental footprint as the majority of our employees work primarily from home, reducing the footprint of our office space and commute-related emissions.

Our telemedicine platform also contributes to the reduction in GHG emissions by enabling our members and their patients to transition to a digital-first healthcare delivery model. We estimate that approximately 3,000 to 3,500 metric tons of carbon dioxide equivalent emissions are avoided for every million virtual visits that would have otherwise been made by car travel. To put this in perspective, 3,000 metric tons of carbon dioxide equivalent represents the emissions of ~650 gasoline powered vehicles driven for a year or the electricity consumption of ~580 homes for a year.

We engaged a third party vendor to calculate our GHG emissions and found that for the calendar years 2021, 2022, and 2023 our combined Scope 1 and Scope 2 location-based GHG emissions were 246, 267, and 314 metric tons of carbon dioxide equivalent, respectively, while our market-based emissions were 258, 299, and 367 respectively.

As we grow, we will continue to assess our environmental impact and search for innovative ways to build a more sustainable business and world.

Non-Employee Director Compensation

Fiscal 2024 Non-Employee Director Compensation Policy

Our non-employee directors were eligible to receive the following cash retainers in fiscal year 2024, paid quarterly in advance, and equity awards pursuant to our director compensation policy:


Annual Retainer for Board Membership
Annual service on the board of directors	$	30,000
Additional retainer lead director	$	15,000
Additional retainer non-executive chair	$	25,000
Additional Annual Retainer for Committee Membership
Annual service as member of the audit committee (other than chair)	$	10,000
Annual service as chair of the audit committee	$	20,000
Annual service as member of the compensation committee (other than chair)	$	6,000
Annual service as chair of the compensation committee	$	12,000
Annual service as member of the nominating and governance committee (other than chair)	$	4,000
Annual service as chair of the nominating and governance committee	$	8,000

Equity
Initial RSU Grant	$ 350,000 (1)
Annual RSU Grant	$ 185,000 (2)

(1) Initial Equity Awards: Our fiscal 2024 policy provided that, upon initial election to our board of directors, each non-employee director would automatically be granted restricted stock units ("RSUs") with a value of $350,000 (the “Initial Grant”), based on the closing price of our common stock over the trailing 30-day period ending on the day immediately prior to the effective date of grant, vesting in equal annual installments over three years, subject to continued service as a director through each applicable vesting date. Each Initial Grant shall accelerate and vest in full upon a Sale Event as defined in our 2021 Stock Option and Incentive Plan (the “2021 Plan”).

(2) Annual Equity Awards: Our fiscal 2024 policy provided that, on the date of each of our annual meetings of stockholders, each continuing non-employee director (other than any such director who received an Initial Grant within the immediately preceding three months) would be automatically granted an RSU grant with a value of $185,000 (the “Annual Grant”), based on the closing price of our common stock over the trailing 30-day period ending on the day immediately prior to the effective date of grant, vesting in full on the earlier of (i) the first anniversary of the Annual Grant or (ii) our next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date. Each Annual Grant shall accelerate and vest in full upon a Sale Event as defined in our 2021 Plan.

We reimburse all reasonable out-of-pocket expenses incurred by directors for their attendance at meetings of our board of directors or any committee thereof.

Employee directors receive no additional compensation for their service as a director.

Fiscal 2024 Non-Employee Director Compensation Table

The following table presents the total compensation paid, awarded or earned with respect to each person who served as a non-employee director in fiscal 2024.


Name	Fees Earned or Paid in Cash ($)	Stock Awards ($)(1)(2)	Total ($)
Kevin Spain (3)	52,000	189,937	241,937
Phoebe L. Yang	40,000	189,937	229,937
Kira Wampler	44,000	189,937	233,937
Regina Benjamin, M.D.	44,000	189,937	233,937
Timothy Cabral	50,000	189,937	239,937

(1)The amounts shown represent the grant date fair value of RSUs granted under our 2021 Plan computed in accordance with Financial Accounting Standards Board ASC Topic 718 referred to as “ASC Topic 718.” Assumptions used in the calculation of these amounts are set forth in Note 2—Summary of Significant Accounting Policies to our audited financial statements for the fiscal year ended March 31, 2024 included in our Annual Report on Form 10-K filed with the SEC on May 23, 2024. Such aggregate grant date fair values do not take into account any estimated forfeitures related to service vesting conditions. The amount reported in this column reflects the accounting costs for these RSUs and does not correspond to the actual economic value that may be received by the directors upon the vesting and/or settlement of the RSUs.

(2)As of March 31, 2024, the number of shares subject to outstanding equity awards held by the non-employee directors was as follows: Mr. Spain: 5,544 shares subject to RSUs; Ms. Yang: 11,320 shares subject to RSUs; Ms. Wampler: 509,700 shares subject to stock options and 5,544 shares subject to RSUs; Dr. Benjamin: 421,138 shares subject to stock options and 5,544 shares subject to RSUs; Mr. Cabral: 483,500 shares subject to stock options and 5,544 shares subject to RSUs.

(3)The cash payment to Mr. Spain is made directly to his employer, Emergence Capital Partners, on his behalf, pursuant to the policy of such employer.

Fiscal 2025 Non-Employee Director Compensation Policy

In May 2024, the Compensation Committee of our Board of Directors reviewed a market analysis by Aon regarding non-employee director compensation. Based on that review, the Committee recommended to the Board that certain increases be made to our director compensation policy in order to better align director compensation with market practices. The Board approved the following compensation levels, effective for fiscal year 2025:


Annual Retainer for Board Membership
Annual service on the board of directors	$	35,000
Additional retainer lead director	$	15,000
Additional retainer non-executive chair	$	25,000
Additional Annual Retainer for Committee Membership
Annual service as member of the audit committee (other than chair)	$	10,000
Annual service as chair of the audit committee	$	20,000
Annual service as member of the compensation committee (other than chair)	$	7,500
Annual service as chair of the compensation committee	$	15,000
Annual service as member of the nominating and governance committee (other than chair)	$	4,500
Annual service as chair of the nominating and governance committee	$	9,000

Equity (1)
Initial RSU Grant	$	400,000.00
Annual RSU Grant	$	200,000.00

(1) All other terms of the equity grants remain the same as described in the table above concerning fiscal year 2024.

EXECUTIVE COMPENSATION

Compensation Discussion and Analysis

Introduction

This Compensation Discussion & Analysis, or CD&A, explains our executive compensation program and the compensation for our named executive officers, NEOs, each of whom is identified in the table below, for the fiscal year ended March 31, 2024. This CD&A also describes our process for making pay decisions, as well as the rationale for specific decisions related to the fiscal year ended March 31, 2024. This CD&A should be read together with the compensation tables and related disclosures for our NEOs.


Named Executive Officer						Position
Jeff Tangney						Chief Executive Officer
Anna Bryson						Chief Financial Officer
Craig Overpeck						SVP, Commercial Operations
Nate Gross, M.D.						Chief Strategy Officer
Jennifer Chaloemtiarana						General Counsel

The discussion in this CD&A contains forward-looking statements that are based on our current considerations and expectations relating to our executive compensation programs and philosophy. As our business needs evolve, and we gain more experience as a public company following our IPO in June 2021, and our transition from emerging growth company status to that of a large accelerated filer at the end of the fiscal year ended March 31, 2023, the actual amount and form of compensation, and the compensation programs, policies and procedures that we adopt may differ materially from current or planned programs, policies and procedures as summarized in this CD&A.

Executive Summary

A Summary of Our Company

We are the leading digital platform for U.S. medical professionals, as measured by the number of U.S. physician members. Our members include more than 80% of U.S. physicians, spanning all 50 states and every medical specialty.

Our mission is to help every physician be more productive and provide better care for their patients. We are physicians-first, putting technology to work for doctors instead of the other way around. That guiding principle has enabled Doximity to become an essential and trusted professional platform for physicians. Our physician cloud puts modern software in the hands of physicians and other medical professionals, enabling our members to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. Our revenue-generating customers, primarily pharmaceutical manufacturers and healthcare systems, have access to a suite of commercial solutions that benefit from broad physician usage.

At the core of our platform is the largest medical professional network in the nation, which creates proximity within our community of doctors and hundreds of thousands of other medical professionals. Verified members can search and connect with colleagues and specialists, which allows them to better coordinate patient care and streamline referrals. Our newsfeed addresses the ever increasing sub-specialization of medical expertise and volume of medical research by delivering news and information that is relevant to each physician's clinical practice. We also support physicians in their day-to-day practice of medicine with mobile-friendly and easy-to-use productivity tools such as voice and video dialer, secure messaging, digital faxing, and Doximity GPT.

Compensation Philosophy and Objectives

We design our executive compensation program to achieve the following objectives:

•Attract, incentivize, retain, and reward top quality management;

•Reward the achievement of aggressive key performance measures (pay for performance);

•Align the interests of our executive officers with the interests of our stockholders and with long-term decision-making; and

•Ensure that executive compensation is meaningfully related to the creation of long-term stockholder value.

We believe the following policies and practices within our executive compensation program promote sound compensation governance and are in the best interests of our stockholders and executive officers. The important features of our executive compensation program include:


What we do						What we don’t do
Our Compensation Committee consists solely of independent members of our board of directors						We do not provide our executive officers with any excise tax gross-ups.
Our Compensation Committee has retained an independent third-party compensation consultant for guidance in making compensation decisions						We do not provide special executive welfare, health benefits, or retirement plans not available to our employees generally
Our Compensation Committee conducts an annual review of our compensation strategy, which includes ensuring that we are not incentivizing excessive risk taking						Our Compensation Committee does not guarantee executive salary increases, bonuses, or equity awards
We ensure that compensation incentives are primarily long-term focused with multi-year vesting and holding periods						We do not permit hedging and pledging of Doximity stock for any employee except for Mr. Tangney, for whom a one-time exception was granted in November 2023 to use certain shares of Doximity Class A common stock owned by him, which represented less than 5% of his overall equity ownership of the Company, as collateral for a loan with a third-party financial institution.
We provide for “double-trigger” equity award vesting upon a change in control of Doximity						We do not provide our executive officers with any material perquisites
We establish accountability through a robust Clawback Policy applicable to certain cash and equity compensation awarded to our executive officers

The Compensation Committee has authority to make compensation decisions regarding the total compensation payable to the Chief Executive Officer and the equity-based compensation payable to the other NEOs. The Chief Executive Officer has authority to make compensation decisions regarding the cash-based elements of compensation payable to the other NEOs. The compensation decisions described throughout this CD&A are made by the Compensation Committee and Chief Executive Officer accordingly.

Our Compensation Committee and Chief Executive Officer closely consider our compensation philosophy and objectives as well as individual and corporate performance when making executive compensation decisions.

Our executive compensation program generally consists of, and is intended to strike a balance among, the following three principal components: annual base salary, short-term incentive compensation in the form of cash or equity awards, and long-term incentive compensation in the form of equity awards. We do not have any formal policies for allocating compensation among these three components. Instead, we intend to establish a total compensation program that is an appropriate mix of short- and long-term incentives to motivate each executive to contribute to the achievement of our corporate objectives. Executive compensation is structured to be heavily weighted towards long-term equity incentives that correlate with the growth of sustainable long-term value for our stockholders, and align the NEOs’ incentives with the interests of our stockholders.

In evaluating our executive compensation policies and programs, as well as the short-term and long-term value of our executive compensation programs, we consider both the individual performance and skills of each of our executive officers, including our NEOs, as well as the compensation paid to executive officers with similar responsibilities at our peer group companies. We focus on providing a competitive compensation package which provides short-term incentives for the achievement of measurable individual objectives and long-term incentives that align with stockholders’ interests. We believe this approach provides an appropriate balance of short-term and long-term incentives to maximize stockholder value.

How We Determine Executive Compensation

Role of the Compensation Committee and Chief Executive Officer in Setting Executive Compensation

Our Compensation Committee is responsible for discharging our board’s responsibilities relating to the compensation of our executive officers and overseeing our overall compensation structure, policies and programs. Our Compensation Committee has delegated the determination of salary and other cash-based compensation payable to our NEOs (other than the Chief Executive Officer), including annual incentive awards, to the Chief Executive Officer, but has retained the authority over all equity-based compensation for such individuals. The Compensation Committee reviews and oversees our executive compensation policies, plans and programs, and reviews and determines the total compensation to be paid to the Chief Executive Officer and the equity compensation to be paid to all other NEOs. Our Compensation Committee consists solely of independent members of the Board. In making its executive compensation determinations for the Chief Executive Officer, the Compensation Committee may also seek recommendations or approval of executive compensation decisions from other independent members of the Board. The Chief Executive Officer does not participate in the discussions and/or determination of his own compensation.

In making cash compensation decisions for executive officers other than himself, the Chief Executive Officer receives input from our human resources department and has access to and considers various third-party compensation surveys and compensation data provided by the independent compensation consultant to the Compensation Committee, as described below.

From time to time, various other members of management as well as outside advisers or consultants, including representatives from its independent compensation consultant, the Human Capital Solutions Practice of Aon plc (“Aon”), are invited by the Compensation Committee to make presentations, provide financial or other background information or advice or otherwise participate in the Compensation Committee meetings. As we gain experience as a public company, we expect that the specific direction, emphasis and elements of our executive compensation program will continue to evolve, as determined by the Compensation Committee.

Role of our Independent Compensation Consultant

The Compensation Committee has the sole authority to retain compensation consultants to assist in its evaluation of executive compensation, including the authority to approve the consultant’s fees and other retention terms. For purposes of evaluating our compensation programs and making compensation decisions, the Committee retained Aon to assist in reviewing Doximity’s compensation programs and to ensure that its compensation programs remain competitive in attracting and retaining talented executives.

In preparation for making compensation decisions, Aon assisted the Compensation Committee in developing a group of peer companies to use as a reference, evaluating current pay practices and considering different compensation programs and best practices, and assisted with reviewing and drafting the CD&A. As described further below, Aon also prepared an analysis of Doximity’s compensation practices with respect to base salaries, short-term incentives and long-term equity incentive grants against market practices to assist in making compensation decisions. Aon reported directly to the Compensation Committee, which maintained the authority to direct their work and engagement, and advised the Compensation Committee from time to time during the fiscal year ended March 31, 2024. Aon interacted with management to gain access to company information that is required to perform services and to understand the culture and policies of Doximity.

The Compensation Committee has assessed the independence of Aon, as required under the NYSE listing rules. The Compensation Committee has also considered and assessed all relevant factors, including, but not limited to, those set forth in Rule 10C-1(b)(4)(i) through (vi) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that could give rise to a potential conflict of interest. Based on this review, the Compensation Committee has determined that Aon is independent and that their work has not raised any conflicts of interest.

Factors Used in Determining Executive Compensation

The compensation of our NEOs is set at levels determined to be competitive and appropriate for each individual NEO, based upon professional experience and judgment, along with market data provided by Aon. Pay decisions are not made by use of a formulaic approach or benchmark; instead, executive pay decisions are based on consideration of a multitude of relevant factors that may vary from year to year and by individual circumstance. In making executive compensation decisions, the factors listed below are generally considered:

•corporate performance, business needs and business impact;

•each NEO’s individual performance, experience, job function, change in position or responsibilities, and expected future contributions to our Company;

•internal pay equity among NEOs and positions;

•the need to attract new talent to our executive team and retain existing talent in a highly competitive industry and geographic region;

•a range of market data reference points provided by Aon, as described below under “Use of Competitive Market Compensation Data”;

•the total compensation cost and stockholder dilution from executive compensation programs;

•trends and compensation paid to similarly situated executive officers within our market;

•a review of each NEO’s total targeted and historical compensation and equity ownership in our Company; and

•non-binding advisory votes by stockholder.

Use of Competitive Market Compensation Data

Doximity aims to attract and retain highly qualified executive officers in an extremely competitive market. Accordingly, the Compensation Committee believes that it is important when making its compensation decisions to be informed as to the current practices of comparable public companies. To this end, the Compensation Committee reviews market data for each executive officer’s position, compiled by Aon, as described below.

In developing a group of peer companies to be used in connection with making compensation decisions, Aon recommended and the Compensation Committee previously selected companies that would be appropriate peers based on economic sector, revenue, geographic region, and market capitalization. The Compensation Committee reviews and updates the peer group and the selection criteria periodically to ensure that the peer group companies satisfy our selection criteria and that such criteria remain appropriate for our size and complexity. As a result of the review of the 2023 peer group, updates were made to establish the peer group for fiscal year 2024 compensation decisions. Specifically, our peer group companies used for the fiscal year ended March 31, 2024 were selected in October 2022, with the following parameters:

•Sector: approximately 80% of peers in the application software industry and approximately 20% of peers in the healthcare technology industry with a focus on high-growth companies where possible;

•Revenue: $150 Million to $1 Billion (increased from $500 Million due to Company growth);

•Market Capitalization: $2 Billion to $18 Billion (increased from a range of $1.5 Billion to $15 Billion); preference for an initial public offering within the last 5 years.

•Headcount: 300 to 3,000 employees

Based on these criteria, Aon recommended and our Compensation Committee approved the following twenty-one member peer group for fiscal year 2024 compensation decisions:


Alteryx, Inc.			Dynatrace, Inc.
American Well Corporation			Elastic N.V.
AppFolio, Inc.			GoodRx, Inc.
Asana, Inc.			Guardant Health, Inc.
Avalara, Inc.			nCino, Inc.
Bill.com, LLC			PagerDuty, Inc.
C3.ai, Inc.			Phreesia, Inc.
Certara, Inc.			Procore Technologies, Inc.
Confluent, Inc.			Samsara Inc.
Coupa Software Inc.			Smartsheet Inc.
Duck Creek Technologies LLC

Based on the changes to the peer group selection criteria, in October 2022. we added eight companies — Certara, Inc., Confluent, Inc., Coupa Software Inc., Dynatrace, Inc., Elastic N.V., Guardant Health Inc., Procore Technologies, Inc. and Samsara, Inc. — to the peer group and removed five companies — Accolade, Inc., Health Catalyst, Inc., Lemonade Insurance Company, SurveyMonkey Inc, and Sumo Logic Inc. — from the peer group. In addition, Medalia, Inc. and Anaplan, Inc. were removed from the peer group because they were acquired. In January 2023, Aon prepared a range of market data reference points based on this peer group. This market data was reviewed, with the assistance of Aon, and used as a reference point in setting the total compensation payable to our NEOs for the fiscal year ended March 31, 2024.

Competitive market positioning is only one of several factors, as described above under “Factors Used in Determining Executive Compensation,” considered in making compensation decisions, and therefore individual NEO compensation may fall at varying levels as compared to the market data.

Fiscal Year 2024 Executive Compensation Program

The following chart summarizes the three main elements of compensation, their objectives, and key features; each as explained in more detail below. We also provide our executive officers, including our NEOs, with benefits available to all of our employees, including retirement benefits under our Section 401(k) plan and participation in various employee health and welfare benefit plans.

Element of Compensation

Objectives

Key Features

Base Salary (fixed cash)

Provides financial stability and security through a fixed amount of cash for performing job responsibilities.

Generally reviewed annually and determined based on a number of factors (including individual performance, internal equity, retention, and the overall performance of our Company) and by reference to market data provided by our independent compensation consultant.

Short-Term Incentive (at-risk performance-based cash and equity)

Annual cash and equity incentives motivate and reward the achievement of the Company’s key business objectives and through the performance of individual performance goals.

Target incentive amounts are reviewed annually and the final payout is dependent upon achievement of individual performance objectives that fall into such NEO’s sphere of influence and that align with our corporate goals.

Long-Term Incentive (at-risk equity)

Motivates and rewards for long-term Company performance; fosters ownership culture, aligns executives’ interests with stockholder interests and the creation of long-term stockholder value. Attracts highly qualified executives and encourages their continued employment over the long-term.

Equity-based awards are generally reviewed and determined annually or as appropriate during the year for new hires, promotions, or other special circumstances, or as an incentive for significant achievement. Individual grants are determined based on a number of factors, including current corporate and individual performance, outstanding equity holdings and their retention value, historical value of our stock and market data provided by our independent compensation consultant.

Base Salary

Base salary represents the fixed portion of the compensation of our NEOs and is an important element of compensation intended to attract and retain highly-talented individuals. In May 2023, the base salaries of the NEOs was reviewed, taking into consideration the executive compensation review undertaken with the help of Aon, and the relevant market data, as well as the other factors described above under “Factors Used in Determining Executive Compensation.” Following this review, the base salary for each of our ongoing NEOs initially was unchanged as compared to fiscal year 2023. Subsequently, on May 1, 2023, Mr. Tangney received an increase in base salary from $240,000 to $300,000 and, on February 1, 2024, Ms. Bryson received an increase in base salary from $300,000 to $400,000, each to better align with peer market data and considering the competitive market for their executive expertise. As a new employee, Mr. Overpeck was hired on May 16, 2023 and received an offer letter outlining his base salary for the year, as described below.

The annual base salaries of each of our NEOs, at the rate in effect at the end of the fiscal year ended March 31, 2024 and 2023, respectively, are listed below:


Names Executive Officer	Fiscal Year 2024 Base Salary ($)	Fiscal Year 2023 Base Salary ($)	Percent Change from 2023 (%)
Jeff Tangney (1)	$300,000	$240,000	25%
Anna Bryson (2)	$400,000	$300,000	33%
Craig Overpeck (3)	$300,000	_
Nate Gross, M.D.	$300,000	$300,000	—%
Jennifer Chaloemtiarana	$300,000	$300,000	—%

_____________

(1)Mr. Tangney’s base salary was $240,000 from April 1, 2023 to April 30, 2023, and was increased to $300,000 on May 1, 2023.

(2)Ms. Bryson’s base salary was $300,000 from April 1, 2023 to January 31, 2024, and was increased to $400,000 on February 1, 2024.

(3)Mr. Overpeck was hired on May 16, 2023.

Short-Term Incentive Compensation

Chief Executive Officer

In the beginning of fiscal year 2024, the Compensation Committee, in consultation with Mr. Tangney, determined that Mr. Tangney would not be provided with an opportunity to earn performance-based incentive compensation for fiscal year 2024. This decision was based on the Committee’s determination that Mr. Tangney’s existing equity holdings were sufficient to align his interests with stockholders’ interests and to properly incentivize him to achieve our corporate goals and objectives for fiscal year 2024.

Other NEOs

Anna Bryson, Craig Overpeck, Nate Gross, and Jennifer Chaloemtiarana were each eligible to receive performance-based incentives for fiscal 2024 designed to drive the achievement of the Company’s revenue and adjusted EBITDA goals as well as to reward the attainment of those goals based on individual performance unique to each NEO. Incentive compensation is based on the achievement of individual performance metrics that are designed to be challenging and rigorous and in alignment with our pay-for-performance philosophy, and, if achieved, we believe will further our overall Company strategy. The individual performance metrics must be achieved for the incentive award to be issued, which may mean there are years in which an NEO does not receive any incentive award even if corporate metrics are met. Target incentive amounts and the associated performance metrics of our NEOs, other than the Chief Executive Officer, are set by the Chief Executive Officer at the beginning of each fiscal year. In establishing these compensation opportunities, the Chief Executive Officer took into account the same factors described under “Factors Used in Determining Executive Compensation” above. The incentives may be in cash or in equity.

For fiscal 2024, the size of the award that could be earned by each of our NEOs who was eligible for such an award was determined in a two-step process.

First, the attainment of an award was based upon the achievement of the Company’s initial fiscal 2024 revenue goal of $503 million and adjusted EBITDA goal of $219 million, each weighted evenly. The revenue and adjusted EBITDA goals represent the midpoint of the stated ranges provided to our stockholders at the beginning of fiscal year 2024. Despite informing our stockholders in August 2023 that our revenue and adjusted EBITDA forecast would be adjusted downward, our Chief Executive Officer determined that targets under the performance-based incentive program would not be likewise adjusted downward but instead retained at originally-established levels. We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, restructuring expense, change in fair value of contingent earn-out consideration liability, and other income, net. The final payout of an award based on these goals could not exceed 120% of the award target for all NEOs except for the Chief Financial Officer for whom the final payout could not exceed 132% .

Second, if the Company’s revenue and adjusted EBITDA goals were achieved, then individual performance would be assessed by our CEO based on the achievement of the pre-established individual performance goals. For fiscal 2024, three

of our NEOs had cash-based incentives based on this framework, and one NEO (Mr. Overpeck) had an equity-based incentive.

Performance-Based Cash Incentives

While our achievement of the revenue and adjusted EBITDA goals established at the beginning of the 2024 fiscal year was at 94.5% and 105.2%, respectively, the achievement of individual performance factors was considered by our Chief Executive Officer for the fiscal year 2024 to increase or decrease each participant’s final incentive award, including to zero but no more than 120% (132% for the Chief Financial Officer) of target. This process resulted in an award for only two of the NEOs. Dr. Gross’ incentive award was based on the achievement of certain new business growth opportunities which was determined not to have been achieved, resulting in no payment. The cash-based target incentive amount and payment earned by each of our NEOs who was eligible for such an award is listed below:


Named Executive Officer	Fiscal Year 2024 Target	Fiscal Year 2024 Incentive Compensation Earned
Anna Bryson	$400,000	$387,612
Nate Gross M.D.	$300,000	$0
Jennifer Chaloemtiarana	$300,000	$299,700

When a cash-based performance incentive is deemed earned by the process described above, it is paid as soon as practicable following such determination, generally in May.

Performance-Based Equity Incentives

As part of his new-hire equity arrangement, Mr. Overpeck was granted performance-based restricted stock units (“PSUs”) valued at approximately $4,000,000 on the grant date, with one-quarter of that amount ($1,000,000 per year) to be issued each of the first four years of employment. The PSUs issued each year would vest based on the achievement of individual performance goals to be established each fiscal year. The target number of shares issuable under Mr. Overpeck’s PSU award was determined by dividing the target grant value of the award by the average closing price of our Class A common stock on the NYSE over the thirty-trading day period prior to the grant date, in order to reduce the impact of daily volatility. If the equity-based performance goals are met, as determined by the Compensation Committee after the end of each applicable fiscal year, the award will be eligible to vest at the threshold, target or maximum level of achievement, subject to Mr. Overpeck’s continued service through each annual vest date.

For the 2024 fiscal year, the target number of shares issuable under Mr. Overpeck’s PSU grant was 29,081 PSUs, and the maximum number of shares issuable was 34,897. Under the two-step process described above, the number of PSUs that were eligible to vest was based upon the achievement of the Company’s initial fiscal 2024 revenue goal of $503 million and adjusted EBITDA goal of $219 million, each weighted evenly, as well as individual performance conditions.

While our achievement of the revenue and adjusted EBITDA goals established at the beginning of the 2024 fiscal year was at 94.5% and 105.2%, respectively, in April 2024, the Compensation Committee determined that the minimum level of the individual performance conditions for the PSU grant, which was on revenue growth of a business line, were not achieved, and the 29,081 RSUs eligible to vest on the basis of 2024 performance were therefore forfeited in their entirety.

Long-Term Incentive Awards

We view long-term incentive compensation in the form of equity awards as a critical component of our executive compensation program, because such awards align the interests of our Chief Executive Officer and our other NEOs with those of our stockholders by incentivizing increases in stockholder value and strengthening retention of our senior management team in the competitive market for talent in which we operate. The size and type of equity awards to be granted is determined by the Compensation Committee, after consultation with the independent compensation consultant and, with respect to the executive officers other than the Chief Executive Officer, the Chief Executive Officer.

The Compensation Committee has determined that employees, including executive officers, would be incentivized and retained by the grant of RSUs given that RSUs have value to the recipient even in the absence of stock appreciation, and therefore achieve such goals using fewer shares of our common stock than would be necessary if we used stock

options. The value of RSUs is directly impacted by the price of our common stock and, therefore, these awards incentivize our NEOs to create long-term value for our stockholders. RSUs tied to a service-based vesting schedule also help us retain qualified executive officers in a highly competitive market for talent. In determining the size of RSU awards, the Compensation Committee takes into account individual performance, internal pay equity considerations, and the value of existing long-term incentive awards.

The equity awards granted to certain of our named executive officers during fiscal year 2024 are set forth in the table below. Noting the current and potential value and remaining vesting of the long-term equity incentive awards granted in prior years to Jeff Tangney, Jennifer Chaloemtiarana and Nate Gross, our Compensation Committee determined that those existing awards provided sufficient retentive and incentive value to such NEOs. Therefore, Mr. Tangney, Ms. Chaloemtiarana and Dr. Gross did not receive an additional RSU grant for fiscal year 2024. See the section titled “Executive Compensation—Outstanding Equity Awards at 2024 Year-End” for more information.

Named Executive Officer

Type of Grant

Shares (#)

Target Value ($)

Anna Bryson (1)

RSUs

104,091

$3,000,000

Craig Overpeck (2)

RSUs

116,326

$4,000,000

_____________

(1)Granted on February 15, 2024 as an additional incentive; vests quarterly over two years.

(2)Granted on May 16, 2023 as part of his new-hire arrangement; vests quarterly over four years.

The number of shares issuable under each of the RSU awards in the table above was determined by dividing the target grant value of the award by the average closing price of our Class A common stock on the NYSE over the thirty-trading day period prior to the grant date, in order to reduce the impact of daily volatility on compensation decisions. The grant date fair value of the RSU awards reported in the “2024 Summary Compensation Table” and the “2024 Grants of Plan-Based Awards Table” is required to be calculated based on our stock price on the grant date, and as a result, such amount may be higher or lower than the target grant value.

Other Features of our Executive Compensation Program

Offer Letters in Place During Fiscal 2023 for Named Executive Officers

We have entered into employment arrangements with our NEOs, including the offer letters described below. The offer letters provide for at-will employment, set forth each executive’s then-current annual base salary, eligibility for annual performance incentive compensation and an initial grant of equity, and eligibility to participate in our benefits plans. Each named executive officer is subject to our confidential information, inventions assignment and arbitration agreements.

Jeffrey Tangney

In April 2010, we entered into an employment offer letter with Mr. Tangney for the position of Chief Executive Officer. The offer letter provides for Mr. Tangney’s at-will employment and sets forth his initial base salary, eligibility to receive annual performance incentive compensation, an initial equity grant and eligibility to participate in our employee benefit health and welfare plans. As mentioned above, for fiscal year 2024, the Compensation Committee decided not to establish a cash incentive goal given his existing equity holdings.

Anna Bryson

On February 4, 2021, we promoted Ms. Bryson to her current position as Chief Financial Officer and entered into an amended employment offer letter with her, replacing her prior employment offer letter of August 2017. The amended offer letter provides for Ms. Bryson’s at-will employment and sets forth her then-current base salary, an initial equity grant, eligibility to receive annual performance incentive compensation and eligibility to participate in our employee benefit health and welfare plans. Pursuant to Ms. Bryson’s amended offer letter, in the event of a termination of her employment by us without Cause or by Ms. Bryson as a result of a Constructive Termination within twelve months following the consummation of a Change in Control (as such capitalized terms are defined in the amended offer letter), Ms. Bryson will be eligible to receive acceleration of 100% of any of her then-outstanding and unvested equity awards, such that all equity awards will become vested and exercisable as of her separation date.

Craig Overpeck

On April 27, 2023, we entered into an offer letter with Mr. Overpeck for the position of Senior Vice President, Commercial Operations. The offer letter provides for his at-will employment and sets forth his initial base salary, an initial equity grant, an equity grant with performance-based vesting, and eligibility to participate in our employee benefit health and welfare plans.

Nate Gross

In February 2021, we promoted Dr. Gross to his current position as Chief Strategy Officer under employment arrangements that replaced his prior employment offer letter, dated February 21, 2012. The terms of Dr. Gross’s at-will promotion include an adjusted base salary, an equity grant, eligibility to receive annual incentive compensation and eligibility to participate in our employee benefit health and welfare plans. We did not enter into a written offer letter setting forth these amended terms.

Jennifer Chaloemtiarana

On August 10, 2020, we entered into an offer letter with Ms. Chaloemtiarana for the position of General Counsel. The offer letter provides for her at-will employment and sets forth her initial base salary, an initial equity grant, eligibility to receive annual performance incentive compensation and eligibility to participate in our employee benefit health and welfare plans. Pursuant to Ms. Chaloemtiarana’s offer letter, in the event of her termination of employment by us without Cause (as defined in the offer letter), Ms. Chaloemtiarana will receive a cash payment in an amount equal to six (6) months of her then-current base salary and a pro-rated portion of her annual incentive compensation (both paid in equal installments over six (6) months) and acceleration of the then-outstanding unvested equity that would have vested during the six (6) months following such termination of employment, so that any such equity awards will vest and become exercisable as of the date of her termination as if she had provided services to the company for an additional six (6) months. In addition, in the event of a termination of Ms. Chaloemtiarana’s employment within twelve months following the consummation of a Change in Control (whether such termination is by us without Cause or by Ms. Chaloemtiarana as a result of Constructive Termination (as each such capitalized term is defined in the offer letter)), Ms. Chaloemtiarana will be eligible to receive a cash payment in an amount equal to six (6) months of her then-current base salary and a pro-rated portion of her annual incentive compensation (both paid in equal installments over six (6) months) and acceleration of 100% of any of her then-outstanding and unvested equity awards, such that all equity awards will become vested and exercisable as of her separation date.

Other Compensation Policies and Practices

Health and Welfare Benefits

Our named executive officers, like all of our full-time employees, are eligible to participate in our health and welfare benefit plans on the same terms as all other full-time employees.

Perquisites

We do not provide significant perquisites or other personal benefits to our executives except as generally made available to our employees. During fiscal year 2024, our NEOs did not receive perquisites or other personal benefits, that were, in the aggregate, $10,000 or more for each individual.

401(k) Plan

We maintain a tax-qualified retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax-advantaged basis (the “401(k) Plan”). Participants in the 401(k) Plan are able to defer eligible compensation subject to applicable annual Internal Revenue Code limits. We provide a matching contribution of 100% of employee contributions up to $3,000 of compensation. The 401(k) Plan is intended to be qualified under Section 401(a) of the Internal Revenue Code with the 401(k) Plan’s related trust intended to be tax exempt under Section 501(a) of the Internal Revenue Code. As a tax-qualified retirement plan, contributions to the 401(k) Plan and earnings on those contributions are not taxable to the employees until distributed from the 401(k) Plan.

Policy Prohibiting Hedging and Pledging of Our Equity Securities

Our insider trading policy prohibits our employees, including our executive officers, and the non-employee members of our Board of Directors, from engaging in short sales, hedging of stock ownership positions, and transactions involving derivative securities relating to our common stock; pledging our securities as collateral for loans; and holding Company securities in margin accounts. However, in November 2023, the Board of Directors granted an exception to the insider trading policy to enable Mr. Tangney to secure a loan using certain shares of Class A common stock as collateral, which represented less than 5% of his overall equity ownership of the Company.

Clawback Policy

Rule 10b5-1 Trading Plans

Our executive officers and directors are encouraged to conduct all purchase or sale transactions under a trading plan established pursuant to Rule 10b5-1 under the Exchange Act. Through a Rule 10b5-1 trading plan, the executive officer or director contracts with a broker to buy or sell shares of our common stock on a periodic basis pursuant to a set of pre-arranged instructions. The broker then executes the trades pursuant to the terms of the plan.

Tax and Accounting Implications

Deductibility of executive compensation. In designing our executive compensation program and determining the compensation of our executive officers, a variety of factors is considered, including the potential impact of the Section 162(m) $1,000,000 deduction limit.

To maintain flexibility to compensate our executive officers in a manner designed to promote our short-term and long-term goals, we have not adopted a policy that all compensation must be deductible. We believe that we should not be constrained by the requirements of Section 162(m) where those requirements would impair our flexibility in attracting and retaining the highest level of talented and experienced executive officers and in compensating our executive officers in a manner that best promotes our strategic objectives.

Taxation of “parachute” payments and deferred compensation. Sections 280G and 4999 of the Code provide that executive officers and directors who hold significant equity interests and certain other service providers may be subject to an excise tax if they receive payments or benefits in connection with a change in control that exceeds certain prescribed limits, and that the Company, or a successor, may forfeit a deduction on the amounts subject to this additional tax. Section 409A of the Code also imposes additional significant taxes on the individual in the event that an executive officer, director, or other service provider receives “deferred compensation” that does not meet the requirements of Section 409A of the Code. We have not agreed to provide our executive officers, including our NEOs, with a “gross-up” or other reimbursement payment for any tax liability that he or she might owe as a result of the application of Section 4999 or Section 409A of the Code.

Accounting treatment. Under ASC Topic 718, we are required to estimate and record expense for each award of equity compensation over the vesting period of the award. We record stock-based compensation expense on an ongoing basis according to ASC Topic 718.

The accounting impact of our executive compensation program is one of many factors that are considered in determining the size and structure of our executive compensation program, so that we can ensure that it is reasonable and in the best interests of our stockholders.

Compensation Risk Assessment

Our Compensation Committee reviews our compensation program, including compensation levels, designs, practices and policies, to understand if there are any areas that are likely to promote excessive risk-taking or create risks that could have a material adverse effect on the Company. Based on the review, we believe that, through a combination of risk-mitigating features and incentives guided by relevant market practices, our compensation programs, policies and practices do not create risks that are reasonably likely to have a material adverse effect on the Company. The following features are noted as strong mitigating features:

•our long-term incentive awards generally vest over time;

•we have a prohibition on hedging and pledging of our common stock except for the one-time exception granted to our Chief Executive Officer;

•we have an independent Compensation Committee; and

•our Compensation Committee engages an independent compensation consultant.

REPORT OF THE COMPENSATION COMMITTEE

The information contained in this compensation committee report shall not be deemed to be “soliciting material,” “filed” with the SEC, subject to Regulations 14A or 14C of the Exchange Act, or subject to the liabilities of Section 18 of the Exchange Act. No portion of this compensation committee report shall be deemed to be incorporated by reference into any filing under the Securities Act, or the Exchange Act, through any general statement incorporating by reference in its entirety the proxy statement in which this report appears, except to the extent that Doximity specifically incorporates this report or a portion of it by reference. In addition, this report shall not be deemed filed under either the Securities Act or the Exchange Act.

Our Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K and contained within this proxy statement with management and, based on such review and discussions, our Compensation Committee recommended to our Board that the Compensation Discussion and Analysis be included in this proxy statement and incorporated into our Annual Report on Form 10-K for the fiscal year ended March 31, 2024.

Compensation Committee:

Kevin Spain (Chair)

Kira Wampler

Phoebe Yang

SUMMARY COMPENSATION INFORMATION

This section provides an overview of the compensation awarded to, earned by, or paid to each of our named executive officers for fiscal 2024. As noted above, our named executive officers (“NEOs”) for fiscal 2024 were:

•Jeffrey Tangney, our Chief Executive Officer;

•Anna Bryson, our Chief Financial Officer;

•Craig Overpeck, our SVP, Commercial Operations;

•Nate Gross, M.D., our Chief Strategy Officer; and

•Jennifer Chaloemtiarana, our General Counsel

2024 Summary Compensation Table

The following table presents the compensation awarded to, earned by, and paid to our named executive officers during fiscal years 2024, 2023, and 2022.


Name and Principal Position	Year	Salary ($)		Stock Awards ($) (1)		Non-Equity Incentive Plan Compensation ($)		All Other Compensation ($)(3)	Total ($)
Jeffrey Tangney, Chief Executive Officer	2024	295,000	(5)	—		—		3,869	298,869
	2023	240,000		—		—		3,726	243,726
	2022	240,000		—		—		3,388	243,388

Anna Bryson, Chief Financial Officer	2024	316,667	(6)	3,158,121		387,612	(4)	3,807	3,866,207
	2023	300,000		—		150,000		3,709	453,709
	2022	300,000		—		100,000		3,211	403,211

Craig Overpeck, SVP, Commercial Operations	2024	262,500		4,901,503	(2)	—		6,836	5,170,839




Nate Gross, Chief Strategy Officer	2024	300,000		—		—	(4)	5,469	305,469
	2023	300,000		1,349,151		150,000		5,535	1,804,686

Jennifer Chaloemtiarana, General Counsel	2024	300,000		—		299,700	(4)	4,241	603,941
	2023	300,000		1,079,306		200,000		4,035	1,583,341

_____________

(1)The amounts reported represent the aggregate grant date fair value of the stock awards granted to our named executive officers during the fiscal year, calculated in accordance with ASC Topic 718. The assumptions used in calculating the grant date fair value of the stock and option awards reported in this column are set forth in Note 11 to our consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024. Such aggregate grant date fair values do not take into account any estimated forfeitures related to service vesting conditions. The amounts reported in this column reflect the accounting cost for these RSUs, PSUs and option awards and do not correspond to the actual economic value that may be received by our named executive officers upon the vesting and/or settlement of the RSU and PSU awards, exercise of the option awards, or any sale of the underlying shares of common stock.

(2)PSU values are included in this amount to the extent that the PSUs have a grant date under FASB ASC Topic 718 in the fiscal year. For purposes of the PSUs, the grant date cannot occur until the applicable performance goals are approved, and therefore this includes the grant date fair value of approximately 1/4th of the target number of PSUs granted to Mr. Overpeck in May 2023. The grant date fair value of the PSUs included within this amount is calculated based on the probable outcome of the performance conditions as of the grant date. Assuming the maximum level of performance achievement, the aggregate grant date fair of the PSUs granted in fiscal 2024 would have been $1,187,196. For more information regarding the accounting for and assumptions we used to calculate the grant date fair values for PSUs, see Note 11 to our consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024.

(3)For fiscal year 2024, the amounts reported represent 401(k) matching contributions, company-paid group life insurance premiums, and wellness benefits for each of our NEOs, and company contributions to health savings accounts for Dr. Gross.

(4)The amounts reported reflect non-equity incentive compensation earned by our NEOs upon the achievement of pre-established performance metrics. See “Compensation Discussion and Analysis—Short-Term Cash Incentive Compensation” for a description of the 2024 annual cash incentive program.

(5)Mr. Tangney’s base salary was increased from $240,000 to $300,000 effective May 1, 2023.

(6)Ms. Bryson’s base salary was increased from $300,000 to $400,000 effective February 1, 2024.

2024 Grants of Plan-Based Awards Table

The following table shows each non-equity incentive plan award and each equity award granted to our named executive officers during fiscal year 2024.


		Estimated future payouts under non-equity incentive plan awards(1)			Estimated future payouts under equity incentive plan awards(2)				All other stock awards: number of shares of stock or units (#)		Grant date fair value of stock and option awards ($)(3)
Name	Grant Date	Threshold ($)	Target ($)	Maximum ($)	Threshold (#)	Target (#)	Maximum (#)
Anna Bryson	N/A	—	400,000	528,000	—	—	—		—		—
	2/15/2024	—	—	—	—	—	—		104,091	(4)	3,158,121
Craig Overpeck	5/16/2023	—	—	—	—	—	—		116,326	(5)	3,939,962
	6/30/2023	—	—	—	9,305	29,081	34,897	(6)	—		961,541
Nate Gross	N/A	—	300,000	360,000	—	—	—		—		—
Jennifer Chaloemtiarana	N/A	—	300,000	360,000	—	—	—		—		—

_____________

(1)The amounts represent the target and maximum amount of non-equity incentive plan awards each NEO could earn in fiscal 2024 under our short-term cash incentive compensation program. See “Compensation Discussion and Analysis—Short-Term Cash Incentive” for a description of the 2024 annual cash incentive program. There is no threshold for the awards granted under the short-term cash incentive compensation program.

(2)Amounts in these columns represent the target, threshold, and maximum units for PSUs with a grant date established under FASB ASC Topic 718 in the fiscal year. For purposes of the PSUs, the grant date cannot occur until the applicable performance goals are determined to have been achieved.

(3)The grant date fair value of each equity award is computed in accordance with FASB ASC 718. The amounts reported in this column reflect the accounting cost for these equity awards as of each respective grant date and do not correspond to the actual economic value that may be received by the NEOs upon the vesting of the equity awards. The amounts for the PSUs granted in fiscal 2024 included within this column reflect the grant date fair value based upon the probable outcome of the performance conditions as of the grant date. For purposes of the PSUs, the grant date cannot occur until the applicable performance goals are determined to have been achieved.

(4)1/8th of the shares subject to this RSU vest on a quarterly basis following February 15, 2024, subject to the NEO’s continuous service relationship with the company through each applicable vesting date.

(5)1/16th of the shares subject to this RSU vest on a quarterly basis following May 15, 2024, subject to the NEO’s continuous service relationship with the company through each applicable vesting date.

(6)The amounts represent the number of PSUs that will vest based upon the achievement of the Company’s initial fiscal 2024 revenue goal of $503 million and adjusted EBITDA goal of $219 million, each weighted evenly, and individual performance conditions that may be used to modify the level of performance, including to zero but no more than 120% of target. The revenue and adjusted EBITDA goals represent the midpoint of the stated ranges provided at the beginning of fiscal year 2024. Adjusted EBITDA is defined as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, restructuring expense, change in fair value of contingent earn-out consideration liability, and other income, net. If the minimum performance conditions were met, PSUs would be issued in an amount that is 32% of target. In April 2024, the Compensation Committee determined that the minimum level of the individual performance conditions were not achieved and therefore the award was forfeited in its entirety.

Outstanding Equity Awards at 2024 Year-End

The following table provides information regarding outstanding equity awards held by our named executive officers as of March 31, 2024.


				Option Awards (1)					Stock Awards (1)
Name	Grant Date	Vesting Commencement Date		Number of Securities Underlying Unexercised Options (#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable	Option Exercise Price ($)	Option Expiration Date		Number of Stock Units That Have Not Vested (#)	Market Value of Stock Units That Have Not Vested ($)(2)
Jeffrey Tangney	6/21/16	5/7/21	(3)	100,000	—	0.60	6/20/26
	6/21/16	3/27/20	(4)	8,334	—	0.60	6/20/26
	3/29/18	3/29/18	(5)	1,792,000	—	0.97	3/28/28
	3/29/18	3/11/18	(6)	846,000	—	0.97	3/28/28
	2/16/21	4/1/22	(7)	1,437,500	2,312,500	8.26	2/15/31
Anna Bryson(14)	5/15/19	5/15/19	(8)	3,952	—	1.50	5/14/29
	6/10/20	5/1/20	(8)	58,324	6,666	1.54	6/9/30
	6/10/20	5/1/20	(9)	23,332	1,668	1.54	6/9/30
	9/29/20	8/21/21	(8)	19,334	11,334	2.21	9/28/30
	12/22/20	8/21/22	(10)	31,666	48,334	4.12	12/21/30
	2/5/21	2/1/21	(7)	397,400	269,868	8.26	2/4/31
	2/15/24	2/15/24	(12)	—	—	—	—	—	104,091	2,801,089





Craig Overpeck	11/29/17	11/29/17	(13)	400	—	0.97	11/28/27
	5/16/23	5/15/23	(11)	—	—	—	—		94,515	2,543,399
	6/30/23	6/30/23	(15)	—	—	—	—		—	—
Nate Gross	6/10/20	5/1/20	(8)	94,618	6,666	1.54	6/9/30
	2/16/21	12/1/24	(8)	—	70,000	8.26	2/15/31
	2/16/21	2/1/21	(8)	122,649	65,542	8.26	2/15/31
	8/15/22	8/15/22	(11)	—	—	—	—		22,814	613,925
Jennifer Chaloemtiarana(14)	9/2/20	8/24/20	(9)	163,544	24,584	2.21	9/1/30
	2/16/21	3/4/21	(8)	834	10,000	8.26	2/15/31
	2/16/21	9/1/24	(8)	—	70,000	8.26	2/15/31
	8/15/22	8/15/22	(11)	—	—	—	—		18,251	491,134

_____________

(1)Unless otherwise described herein, each option grant is subject to the terms of our 2010 Plan and each RSU is subject to the terms of our 2021 Plan.

(2)The market value of the outstanding RSUs was calculated by multiplying the number of shares shown in the Table by $26.91, which was the closing market price of Doximity's Class A common stock on March 31, 2024, the last trading day of our fiscal year.

(3)This option became fully vested on May 7, 2022.

(4)This option became fully vested on March 27, 2021.

(5)This option became fully vested on May 31, 2022.

(6)This option became fully vested on March 11, 2022.

(7)1/60th of the shares subject to the stock option vest on a monthly basis following the vesting commencement date, subject to the named executive officer’s continuous service relationship with the company through each applicable vesting date.

(8)1/48th of the shares subject to the stock option vest on a monthly basis following the vesting commencement date, subject to the named executive officer’s continuous service relationship with the company through each applicable vesting date.

(9)1/4th of the shares subject to the stock option vest on the first anniversary of the vesting commencement date and the remaining shares vest in 36 equal monthly installments thereafter, subject to the named executive officer’s continuous service relationship with the company through each applicable vesting date.

(10)1/48th of the shares subject to the stock option vest on a monthly basis following the fifth anniversary of Ms. Bryson’s hire date, August 21, 2022, subject to the named executive officer’s continuous service relationship with the company through each applicable vesting date.

(11)1/16th of the shares subject to this RSU vest on a quarterly basis following the vesting commencement date, subject to the named executive officer’s continuous service relationship with the company through each applicable vesting date.

(12)1/8th of the shares subject to this RSU vest on a quarterly basis following the vesting commencement date, subject to the named executive officer’s continuous service relationship with the company through each applicable vesting date.

(13)This option was issued in connection with consulting work conducted by Mr. Overpeck for the Company prior to his hire, and it fully vested on November 29, 2017.

(14)All unvested awards for the NEO are subject to vesting acceleration under certain circumstances pursuant to the terms of the RSU or option agreement, as described in the section titled “Potential Payments upon Termination or Change in Control” below.

(15)The shares subject to this PSU were forfeited in April 2024, when the Compensation Committee determined that the minimum level of the individual performance conditions for the first tranche of his PSU were not achieved. For purposes of the PSUs, the grant date cannot occur until the applicable performance goals are approved, and therefore we have excluded the approximately 3/4th of the target number of PSUs granted to Mr. Overpeck in May 2023, which represents the remaining tranches, for which a performance condition had not been set as of March 31, 2024.

2024 Options Exercised and Stock Vested Table

The following table provides information on stock option exercises and shares acquired on the vesting of stock awards by our named executive officers during fiscal year 2024.


	Option Awards		Stock Awards
Name	Number of Shares Acquired on Exercise (#)	Value Realized on Exercise ($)(1)	Number of Shares Acquired on Vesting (#)	Value Realized on Vesting ($)(2)
Jeff Tangney	—	—	—	—
Anna Bryson	35,000	717,150	—	—
Craig Overpeck	—	—	29,181	821,532
Nate Gross	119,993	2,840,800	9,126	256,734
Jennifer Chaloemtiarana	13,997	328,153	7,301	205,390

(1)The value realized on exercise is computed by multiplying the difference between the exercise price and the closing stock price of our Class A common stock on the date of exercise by the number of shares subject to the stock option that were exercised.

(2)The value realized on vesting is computed by multiplying the number of shares subject to the RSU that vested by the closing stock price of our Class A common stock on the vest date.

Potential Payments upon Termination or Change in Control

The following describes and quantifies the estimated amounts payable under existing plans and contractual arrangements we have entered into with our named executive officers, assuming a qualifying termination of employment occurred on March 31, 2024, based on the closing market price of our Class A common stock of $26.91 on March 28, 2024, the immediately preceding trading date.

Anna Bryson: Pursuant to Ms. Bryson’s amended offer letter, in the event of a termination of her employment by us without Cause or by Ms. Bryson as a result of a Constructive Termination within twelve months following the consummation of a Change in Control (as such capitalized terms are defined in the amended offer letter), Ms. Bryson will be eligible to receive acceleration of 100% of any of her then-outstanding and unvested equity awards, such that all equity awards will become vested and exercisable as of her separation date. Had such a qualifying termination of employment occurred on March 31, 2024, the value of the accelerated vesting of Ms. Bryson’s outstanding equity awards would have been $9,427,042.

Jennifer Chaloemtiarana: Pursuant to Ms. Chaloemtiarana’s offer letter, in the event of her termination of employment by us without Cause (as defined in the offer letter), Ms. Chaloemtiarana will receive a cash payment in an amount equal to six (6) months of her then-current base salary and a pro-rated portion of her annual incentive compensation (both paid in equal installments over six (6) months) and acceleration of the then-outstanding unvested equity that would have vested during the six (6) months following such termination of employment, so that any such equity awards will vest and become exercisable as of the date of her termination as if she had provided services to the company for an additional six (6) months. Had such a qualifying termination of employment for Ms. Chaloemtiarana occurred on March 31, 2024, the value of the cash salary severance would have been $150,000, the value of the cash annual incentive compensation would have been $150,000, and the value of the accelerated vesting of her outstanding equity awards would have been $798,696, for a total value of $1,098,696. In addition, in the event of a termination of Ms. Chaloemtiarana’s employment within twelve months following the consummation of a Change in Control (whether such termination is by us without Cause or by Ms. Chaloemtiarana as a result of Constructive Termination (as each such capitalized term is defined in the offer letter)), Ms. Chaloemtiarana will be eligible to receive a cash payment in an amount equal to six (6) months of her then-current base salary and a pro-rated portion of her annual incentive compensation (both paid in equal installments over six (6) months) and acceleration of 100% of any of her then-outstanding and unvested equity awards, such that all equity awards will become vested and exercisable as of her separation date. Had such a qualifying termination of employment for Ms. Chaloemtiarana occurred on March 31, 2024, the value of the cash salary severance would have been $150,000, the value of the cash annual incentive compensation would have been $150,000, and the value of the accelerated vesting of her outstanding equity awards would have been $2,590,359, for a total value of $2,890,359.

Craig Overpeck: Pursuant to the terms of the PSU grant issued to Mr. Overpeck, in the event of a ”sale event” as defined under our 2021 Plan prior to the completion of the performance period for the PSUs, Mr. Overpeck would be eligible to receive that number of shares that the Compensation Committee had determined had been earned as of the date of the sale event. Had a termination of Mr. Overpeck’s employment occurred on March 31, 2024, Mr. Overpeck would not have been eligible to receive any of the underlying shares subject to his PSU grant.

In addition, the Company’s equity plans provide for certain contingent benefits upon a change in control as described below:

The 2010 Equity Incentive Plan (the “2010 Plan”) provides that in the event of a merger or a “Change in Control,” as defined in the 2010 Plan, each outstanding award is treated as our board determines without participant consent. Outstanding awards may be (i) assumed or substituted by an acquiring company; (ii) upon written notice to participants, terminate upon or immediately prior to the Change in Control or merger; (iii) vest and become exercisable, or restrictions will lapse, in whole or in part prior to the Change in Control or merger; (iv) terminate for an amount of cash or property equal to what the participant would have received on exercise or realization of the award, if any; or (v) any combination of the foregoing. However, in the event that the acquiring company does not assume or substitute awards, (x) all vesting on options and stock appreciation rights shall fully accelerate and become exercisable, (y) all restrictions on restricted stock and restricted stock units will lapse, and (z) any performance-based vesting and performance goals or other vesting criteria will be deemed achieved at one-hundred percent of goal.

The 2021 Plan, provides that upon the effectiveness of a “sale event,” as defined in our 2021 Plan, an acquirer or successor entity may assume, continue or substitute for the outstanding awards under our 2021 Plan. To the extent that awards granted under our 2021 Plan are not assumed or continued or substituted by the successor entity, all unvested awards granted under our 2021 Plan shall terminate. In such case, except as may be otherwise provided in the relevant award agreement, all options and stock appreciation rights with time-based vesting, conditions or restrictions that are not vested and exercisable immediately prior to the sale event will become fully vested and exercisable as of the sale event, all other awards with time-based vesting, conditions, or restrictions will become fully vested and nonforfeitable as of the sale event, and all awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with the sale event at the plan administrator’s discretion or to the extent specified in the relevant award agreement.

CEO PAY RATIO

Under rules adopted pursuant to the Dodd-Frank Act, we are required to disclose the ratio of the total compensation paid to the median employee as compared to the total compensation paid to our Chief Executive Officer (the “CEO Pay Ratio”). The paragraphs that follow describe our methodology and the resulting CEO Pay Ratio. The annual total compensation for 2024 for our CEO, Mr. Tangney was $298,869 as reported under the heading “Summary Compensation Table.” Our median employee's annual total compensation for 2024 was $160,672, calculated using the same methodology as that for our CEO which includes both cash and equity based compensation. As a result, we estimate that Mr. Tangney's 2024 total compensation was approximately 1.86 times that of our median employee.

Our CEO to median employee pay ratio was calculated in accordance with Item 402(u) of Regulation S-K. We identified the median employee using our employee population on March 31, 2024 (including all employees, whether employed on a full-time, part-time, seasonal or temporary basis). We did not include any contractors or other non-employee workers in our employee population.

To identify the median employee, we used a consistently applied compensation measure consisting of annual base pay, actual commissions, actual bonuses, and the grant date fair value of equity awards granted to our employees during the fiscal year ended March 31, 2024. Compensation for new hire employees that commenced employment in fiscal year 2024 was annualized to reflect a full year.

This information is being provided for compliance purposes and is a reasonable estimate calculated in a manner consistent with SEC rules, based on our internal records and the methodology described above. The SEC rules for identifying the median compensated employee allow companies to adopt a variety of methodologies, to apply certain exclusions and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices. Accordingly, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies have different employee populations and compensation practices and may use different methodologies,

exclusions, estimates and assumptions in calculating their own pay ratios. Neither the Compensation Committee nor management of the company used the CEO Pay Ratio measure in making compensation decisions.

PAY VERSUS PERFORMANCE

The following tables set forth information concerning the compensation of our named executive officers and our financial performance for the fiscal years ended March 31, 2024, 2023, and 2022.

Pay Versus Performance

As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between executive compensation actually paid to our Chief Executive Officer, who is our principal executive officer (“PEO”) and the other NEOs, as calculated in accordance with Item 402(v) of Regulation S-K, and certain financial performance measures. For further information concerning the Company’s pay-for-performance philosophy and how the Company aligns executive compensation with the Company’s performance, refer to “Fiscal 2024 Executive Compensation Program—Compensation Discussion and Analysis.”

Pay Versus Performance Table

The following table summarizes compensation values reported in the Summary Compensation Table (“SCT”) for our PEO and the average for our other NEOs, as compared to Compensation Actually Paid (“CAP”) and the Company’s financial performance for the fiscal years ended March 31, 2024, 2023, and 2022:


					Value of Initial Fixed $100 Investment Based On:(4)
Year(1)	Summary Compensation Table Total for PEO ($)	Compensation Actually Paid to PEO ($)(2)(3)	Average Summary Compensation Table Total for Non-PEO NEOs ($)	Average Compensation Actually Paid to Non-PEO NEOs ($)(2)(3)	Total Shareholder Return(5) ($)	Peer Group Shareholder Return ($)(6)	Net Income (Millions) ($)	Revenue (Millions) ($)(7)
(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)
2024	298,869	(15,679,931)	2,486,614	657,221	50.77	153.41	147.6	475.4
2023	243,726	(101,686,366)	1,074,218	(7,298,566)	61.09	105.07	112.8	419.1
2022	243,388	217,519,085	3,225,392	23,272,821	98.28	110.08	154.8	343.5

_____________

(1)The following individuals were our Non-PEO NEOs in the respective years:

2024: Anna Bryson, Craig Overpeck, Nate Gross, Jennifer Chaloemtiarana

2023: Anna Bryson, Paul Jorgensen, Nate Gross, Jennifer Chaloemtiarana

2022: Anna Bryson, Paul Jorgensen, Joseph Kleine

(2)The dollar amounts reported in column (c) and (e) represent the CAP to our PEO and the average CAP to our other NEOs as a group, respectively, as computed in accordance with Item 402(v) of Regulation S-K, and do not reflect the actual amount of compensation earned by or paid to our PEO or our other NEOs as a group during the applicable year.

(3)In accordance with Item 402(v) of Regulation S-K, the following adjustments were made to the 2024 amount reported for our PEO and our other NEOs as a group in the “Total” column of the Summary Compensation Table for each year to calculate CAP. For information on the calculation of “compensation actually paid” for 2023 and 2022, please see the “pay versus performance” disclosure in our 2023 definitive proxy statement which was filed with the SEC on June 14, 2023.


	2024
	Jeff Tangney	Average Non-PEO NEOs
Total Compensation from SCT	298,869	2,486,614
Adjustments for equity awards:
Grant date values in the SCT	—	(2,014,906)
Year-end fair value of unvested awards granted in the current year	—	1,336,122
Fair values at vest date for awards granted and vested in current year	—	142,480
Change in fair values from prior year-end to current year-end of unvested awards granted in prior years	(12,965,556)	(873,480)
Change in fair values from prior year-end to vest date of awards granted in prior years that that vested in the year	(3,013,244)	(419,609)
Forfeitures during current year equal to prior year-end fair value	—	—
Dividends or dividend equivalents not otherwise included in total compensation	—	—
Total Adjustments for Equity Awards	(15,978,800)	(1,829,393)
Compensation Actually Paid	(15,679,931)	657,221

(4)The Company and the Peer Group total shareholder return is determined based on the value of an initial fixed investment of $100 on June 24, 2021 (the date that our Class A common stock commenced trading on the NYSE) through the end of the listed year, and assumes that all dividends were reinvested.

(5)Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between the Company’s share price at the end and the beginning of the measurement period by the Company’s share price at the beginning of the measurement period.

(6)Represents the weighted peer group TSR of the S&P 500 Information Technology Index, weighted according to the respective companies’ stock market capitalization at the beginning of each period for which a return is indicated.

(7)While the Company uses numerous financial and non-financial performance measures for the purpose of evaluating performance for the Company’s compensation programs, the Company has determined that Revenue is the financial performance measure that, in the Company’s assessment, represents the most important performance measure used by the Company to link compensation actually paid to the Company’s NEOs, for the most recently completed fiscal year, to Company performance.

Financial Performance Measures

As described in greater detail in the “Compensation Discussion and Analysis” section above, the Company’s executive compensation program reflects a pay-for-performance philosophy. The metrics that we use for both our long-term and short-term incentive awards are selected based on an objective of incentivizing our NEOs to increase the value of our enterprise for our stockholders. Below is an unranked list of all financial performance measures that we used to link Compensation Actually Paid to the Company’s NEOs for the most recently completed fiscal year to the Company’s performance:

•Revenue

•Adjusted EBITDA (1)

(1) We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, restructuring expense, change in fair value of contingent earn-out consideration liability, and other income, net.

Relationship Between Compensation Actually Paid and Financial Performance Measures

As required by SEC rules, we are providing in this section a graphic analysis showing a comparison of the CAP to our NEOs and the other metrics presented in the Pay Versus Performance table: total stockholder return, net income, and revenue.

Relationship between CAP, Cumulative Total Shareholder Return (“TSR”) of the Company and Cumulative TSR of the Peer Group

The graph below illustrates the relationship between CAP for our PEO, the average of CAP for our Non-PEO NEOs, the Company's cumulative TSR, and the cumulative TSR of the S&P 500 Information Technology Index for each of the periods presented in the Pay Versus Performance table.

Relationship Between CAP and Net Income

The graph below illustrates the relationship between the CAP for our PEO, the average of CAP for our Non-PEO NEOs, and the Company's net income for each of the periods presented in the Pay Versus Performance table.

Relationship Between CAP and Revenue

The graph below illustrates the relationship between the CAP for our PEO, the average of CAP for our Non-PEO NEOs, and the Company's revenue for each of the periods presented in the Pay Versus Performance table.

EQUITY COMPENSATION PLAN INFORMATION

The following table shows certain information with respect to all of our equity compensation plans, including the 2010 Plan, 2021 Employee Stock Purchase Plan (the “2021 ESPP”) and the 2021 Plan, in effect as of March 31, 2024, as well as shares that may be issued pursuant to warrants and options issued under arrangements outside of the 2010 Plan, 2021 ESPP, and the 2021 Plan.


	Equity Compensation Plan Information
Plan category	(a) Number of Securities to be Issued upon Exercise of Outstanding Options, Warrants and Rights		(b) Weighted Average Exercise Price of Outstanding Options, Warrants and Rights		(c) Number of Securities Remaining Available for Future Issuance under Equity Compensation Plan (Excluding Securities Referenced in Column (a))
Equity compensation plans approved by security holders (1)	17,360,649	(2)	5.25	(3)	48,825,279	(4)
Equity compensation plans not approved by security holders	3,154,000	(5)	2.87		N/A
Total	20,514,649		4.83	(3)	48,825,279

_____________

(1)The number of shares reserved and available for issuance under the 2021 Plan will automatically increase each April 1 by 5% of the outstanding number of shares of our Class A and Class B common stock as of the immediately preceding March 31, or such lesser number of shares as determined by our compensation committee. The number of shares reserved and available for issuance under the 2021 ESPP will automatically increase each April 1 through April 1, 2031, by the lesser of 6,750,000 shares of our Class A common stock, 1% of the outstanding number of shares of our Class A common stock and Class B common stock on the immediately preceding March 31, or such lesser number of shares as determined by our compensation committee. As of March 31, 2024, a total of 43,342,545 shares of our Class A common stock have been reserved for issuance pursuant to the 2021 Plan, which number excludes the 1,865,616 shares that were added to the 2021 Plan as a result of the automatic annual increase on April 1, 2024. The Company no longer makes grants under the 2010 Plan. As of March 31, 2024, a total of 8,001,836 shares of our Class A common stock have been reserved for issuance pursuant to the 2021 ESPP, which number excludes the 1,865,616 shares that were added to the 2021 ESPP as a result of the automatic annual increase on April 1, 2024.

(2)Includes 14,841,547 shares of Class B common stock issuable upon the exercise of outstanding options and 2,519,102 shares of Class A common stock issuable upon the vesting of RSUs.

(3)As RSUs do not have any exercise price, such units are not included in the weighted average exercise price calculation.

(4)As of March 31, 2024, there were 40,823,443 shares of Class A common stock available for grant under the 2021 Plan and 8,001,836 shares of Class A common stock available for grant under the 2021 ESPP.

(5)Includes shares of common stock issuable upon the exercise of outstanding options granted to Mr. Tangney outside of the 2010 Plan, as described in the “Outstanding Equity Awards at 2024 Year-End” table and shares of common stock issuable upon the exercise of warrants granted to U.S. News & World Report, L.P.

PROPOSAL THREE:

NON-BINDING ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS

As required by Section 14A of the Securities Exchange Act of 1934 (which was added by the Dodd-Frank Wall Street Reform and Consumer Protection Act and the related rules of the SEC, or the Dodd-Frank Act), we are providing our stockholders with the opportunity to cast a non-binding advisory vote to approve the compensation of our named executive officers at the Annual Meeting. This proposal, commonly known as a “say-on-pay” proposal, gives our stockholders the opportunity to express their views on the design and operation of our executive officers compensation program. We currently hold our non-binding, advisory say-on-pay vote every year. Stockholders will have an opportunity to cast an advisory vote on the frequency of the say-on-pay votes at least every six years. We currently expect that the next non-binding advisory vote on the frequency of the say-on-pay votes will occur at the annual meeting of stockholders held in 2029.

Our executive compensation program is intended to attract, incentivize, retain, and reward top quality management; pay for performance; align the interests of our executive officers with the interests of our stockholders; and ensure that executive compensation is meaningfully related to the creation of long-term stockholder value. This vote is not intended to address any specific item of compensation or the compensation of any specific named executive officer, but rather the overall compensation of all of our named executive officers described in this proxy statement. The compensation of our named executive officers is disclosed in the section of this proxy statement titled “Executive Compensation”, which consists of the Compensation Discussion and Analysis, the Summary Compensation Table, the ancillary compensation tables, and the related narrative disclosure contained therein. We believe that our named executive officer compensation program is competitive within our industry and strongly aligned with the long-term interests of our stockholders.

For these reasons, our Board recommends a vote, on an advisory basis, in favor of the compensation of our named executive officers.

Vote Required

As an advisory vote, this proposal is not binding upon the Company, our Board or our Compensation Committee. Notwithstanding the advisory nature of this vote, our Board and our Compensation Committee value the opinions expressed by our stockholders in their vote on this proposal, and will consider the outcome of the vote when making future compensation decisions for our executive officers. Approval of this proposal requires the affirmative vote of a majority of the votes present and entitled to vote on the proposal that are present in person or represented by proxy at the Annual Meeting and are voted for or against this proposal. Stockholders may vote “for” or “against” the proposal, or they may abstain from voting on the proposal. Abstentions will have the same effect of a vote “Against” the Say-on-Pay Proposal. Broker non-votes will have no effect on the outcome of this proposal.

Recommendation of our Board

OUR BOARD RECOMMENDS A VOTE “FOR” THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS.

SECURITY OWNERSHIP OF

CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information with respect to the beneficial ownership of our common stock as of April 1, 2024, for:

•each of our named executive officers for fiscal 2024;

•each of our directors;

•all of our directors and executive officers as a group; and

•each person known by us to be the beneficial owner of more than five percent of the outstanding shares of our Class A or Class B common stock.

We have determined beneficial ownership in accordance with the rules of the SEC, and thus it represents sole or shared voting or investment power with respect to our securities. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable.

We have based percentage ownership of our common stock on 124,032,767 shares of our Class A common stock and 62,463,784 shares of our Class B common stock outstanding as of April 1, 2024. We have deemed shares of our common stock subject to options that are currently exercisable or exercisable within 60 days of April 1, 2024 to be outstanding and to be beneficially owned by the person holding the option for the purpose of computing the percentage ownership of that person. We have deemed shares of our common stock subject to restricted stock unit awards for which the service condition has been satisfied or would be satisfied within 60 days of April 1, 2024 to be outstanding and to be beneficially owned by the person holding the restricted stock unit awards for the purpose of computing the percentage ownership of that person. However, we did not deem these shares subject to stock options or restricted stock unit awards outstanding for the purpose of computing the percentage ownership of any other person.

Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o Doximity, Inc., 500 3rd St., Suite 510, San Francisco, CA 94107.


	Shares Beneficially Owned
	Class A			Class B §			Total Voting%†		Total Ownership%
	Shares	%		Shares	%
5% Stockholders:
Entities affiliated with Tangney Schweikert Family Trust(1)	—	*		44,203,330	70.8	%	59.0	%	26.3	%
Entities affiliated with Emergence Capital Partners II, L.P.(2)	775,000	*		12,534,728	20.1	%	16.8	%	9.7	%
Entities affiliated with The Vanguard Group(3)	10,900,648	8.8	%	—	*		1.5	%	8.8	%
Entities affiliated with BlackRock, Inc.(4)	10,540,334	8.5	%	—	*		1.4	%	8.5	%
Entities affiliated with Morgan Stanley(5)	6,749,692	5.4	%	—	*		*		5.4	%
Entities affiliated with Baillie Gifford & Co(6)	6,299,503	5.1	%	—	*		*		5.1	%
Named Executive Officers and Directors:
Jeffrey Tangney(7)	2,299,350	1.9	%	52,783,830	79.1	%	67.0	%	31.2	%
Regina Benjamin(8)	4,714	*		421,138	*		*		*
Timothy Cabral(9)	—	*		483,500	*		*		*
Kevin Spain(10)	957,665	*		12,534,728	20.1	%	16.9	%	9.9	%
Kira Wampler(11)	4,714	*		507,200	*		*		*
Phoebe Yang(12)	2,889	*		—	*		*		*
Anna Bryson(13)	152,774	*		570,478	*		*		*
Jennifer Chaloemtiarana(14)	7,725	*		175,878	*		*		*
Nate Gross(15)	484,985	*		235,849	*		*		*
Craig Overpeck(16)	25,727	*		400	*		*		*
All directors and executive officers as a group (10 persons)(17)	3,940,543	3.2	%	67,713,001	97.9	%	83.5	%	37.4	%

_____________

* Represents less than one percent (1%).

† Percentage of total voting power represents voting power with respect to all shares of our Class A common stock and Class B common stock, as a single class. The holders of our Class A common stock are entitled to one vote per share, and holders of our Class B common stock are entitled to ten votes per share.

§ The Class B common stock is convertible at any time by the holder into shares of Class A common stock on a share-for-share basis.

(1)Consists of (i) 24,203,330 shares of Class B common stock held of record by Tangney Schweikert Family Trust, of which Jeffrey Tangney and his spouse, Claudia Schweikert, are trustees, and (ii) 20,000,000 shares of Class B common stock held of record by Tangney Annuity Trust, LLC, of which Ms. Schweikert is the sole manager.

(2)Consists of (i) 12,534,728 shares of Class B common stock held by Emergence Capital Partners II, L.P., or ECP II, and (ii) 775,000 shares of Class A common stock held by Emergence Capital Opportunity I, L.P, or ECO I. Emergence Equity Partners II, L.P., or EEP II, is the sole general partner of ECP II and may be deemed to beneficially own shares held by ECP II. Emergence Equity Partners VI, L.P., or EEP VI, is the sole general partner of ECO I, and may be deemed to beneficially own shares held by ECO I. Emergence GP Partners, LLC, or EGP, is the sole general partner of EEP II and the sole general partner of EEP VI, and may be deemed to beneficially own shares held by ECP II and ECO I. Kevin Spain is a partner of EEP II and shares voting and dispositive power over the shares held by ECP II. Mr. Spain is also a member of our board of directors, and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The address for ECP II is 5 Pier, Suite 102, San Francisco, CA 94111.

(3)Beneficial ownership information is based on information contained in the Schedule 13G/A filed with the SEC on February 13, 2024 by The Vanguard Group. Consists of 10,900,648 shares of Class A common stock held of record by The Vanguard Group. The Vanguard Group has shared voting power over 43,468 shares, sole dispositive power over 10,732,765 shares and shared dispositive power over 167,883 shares. The address for The Vanguard Group is 100 Vanguard Blvd., Malvern, PA 19355.

(4)Beneficial ownership information is based on information contained in the Schedule 13G/A filed with the SEC on January 25, 2024 by BlackRock, Inc. Consists of 10,540,334 shares of Class A common stock held of record by BlackRock, Inc. BlackRock, Inc has sole voting power over 10,178,368 shares and sole dipositive power over 10,540,334 shares. The address for BlackRock, Inc is 50 Hudson Yards New York, NY 10001.

(5)Beneficial ownership information is based on information contained in the Schedule 13G/A filed with the SEC on February 8, 2024 by Morgan Stanley. Consists of 6,749,692 shares of Class A common stock held of record by Morgan Stanley. Morgan Stanley has shared voting power over 6,138,353 shares and shared dispositive power over 6,723,602 shares. Morgan Stanley Investment Management Inc., is a wholly-owned subsidiary of Morgan Stanley and may be deemed to beneficially own shares held by Morgan Stanley. The address for Morgan Stanley is 1585 Broadway, New York, NY 10036.

(6)Beneficial ownership information is based on information contained in the Schedule 13G/A filed with the SEC on January 30, 2024 by Baillie Gifford & Co. Consists of 6,299,503 shares of Class A common stock held of record by Baillie Gifford & Co. Baillie Gifford & Co. has sole voting power over 6,103,939, shares and sole dispositive power over 6,299,503 shares. The address for Baillie Gifford & Co is Calton Square, 1 Greenside Row, Edinburgh, EH1 3AN, Scotland, UK.

(7)Consists of (i) 24,203,330 shares of Class B common stock held of record by Tangney Schweikert Family Trust, of which, Jeffrey Tangney, and his spouse, Claudia Schweikert, are trustees, (ii) 20,000,000 shares of Class B common stock held of record by Tangney Annuity Trust, LLC, of which Ms. Schweikert is the sole manager, (iii) 4,271,666 shares of Class B common stock held of record by Mr. Tangney, (iv) 2,299,350 shares of Class A common stock held of record by Mr. Tangney, which includes 1,900,000 shares of Class A common stock pledged as collateral to secure certain personal indebtedness, and (v) 4,308,834 shares of Class B common stock subject to outstanding stock options that are exercisable within 60 days of April 1, 2024.

(8)Consists of (i) 4,714 shares of Class A common stock and (ii) 421,138 shares of Class B common stock subject to outstanding options that are exercisable within 60 days of April 1, 2024.

(9)Consists of 483,500 shares of Class B common stock subject to outstanding options that are exercisable within 60 days of April 1, 2024.

(10)Consists of (i) 12,534,728 shares of Class B common stock held by ECP II, (ii) 775,000 shares of Class A common stock held by ECO I as reflected in footnote (2) above, and (iii) 182,665 shares of Class A common stock held of record by The Spain-Goralnik Family Trust 12/7/12. Mr. Spain, a member of our board of directors, is a partner of EEP II and shares voting and dispositive power with regard to the shares directly held by ECP II. Mr. Spain disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

(11)Consists of (i) 4,714 shares of Class A common stock and (ii) 507,200 shares of Class B common stock subject to outstanding options that are exercisable within 60 days of April 1, 2024.

(12)Consists of 2,889 shares of Class A common stock.

(13)Consists of (i) 139,763 shares of Class A common stock, (ii) 13,011 shares of Class A common stock subject to RSUs that vest within 60 days of April 1, 2024, and (iii) 570,478 shares of Class B common stock subject to outstanding options that are exercisable within 60 days of April 1, 2024.

(14)Consists of (i) 5,900 shares of Class A common stock, (ii) 1,825 shares of Class A common stock subject to RSUs that vest within 60 days of April 1, 2024, and (iii) 175,878 shares of Class B common stock subject to outstanding options that are exercisable within 60 days of April 1, 2024.

(15)Consists of (i) 362,706 shares of Class A common stock, (ii) 119,998 shares of Class A common stock held by Nathan Gross 2021 Annuity Trust U/A, of which Mr. Gross is trustee (iii) 2,281 shares of Class A common stock subject to RSUs that vest within 60 days of April 1, 2024, and (iv) 235,849 shares of Class B common stock subject to outstanding options that are exercisable within 60 days of April 1, 2024.

(16)Consists of (i) 18,456 shares of Class A common stock, (ii) 7,271 Class A common stock subject to RSUs that vest within 60 days of April 1, 2024, and (iii) 400 shares of Class B common stock subject to outstanding options that are exercisable within 60 days of April 1, 2024.

(17)Consists of (i) 3,916,155 shares of Class A common stock beneficially owned by our current directors and executive officers, (ii) 24,388 shares of Class A common stock subject to RSUs held by our current directors and executive officers that vest within 60 days of April 1, 2024, (ii) 61,009,724 shares of Class B common stock beneficially owned by our current directors and executive officers, and (iv) 6,703,277 shares of Class B common stock subject to outstanding options that are exercisable within 60 days of April 1, 2024.

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

Certain Relationships and Transactions

In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements and indemnification arrangements, discussed, when required, in the sections titled “Executive Officers” and “Executive Compensation” the following is a description of each transaction since April 1, 2023 and each currently proposed transaction in which:

•we have been or are to be a participant;

•the amount involved exceeded or exceeds $120,000; and

•any of our directors, executive officers or holders of more than 5% of our capital stock, or any immediate family member of, or person sharing the household with, any of these individuals, had or will have a direct or indirect material interest.

Investors’ Rights Agreement

We are party to an investors’ rights agreement which provides, among other things, that certain holders of our capital stock have the right to demand that we file a registration statement or request that their shares of our capital stock be covered by a registration statement that we are otherwise filing. The parties to the investors’ rights agreement include Jeffrey Tangney, our Chief Executive Officer and a current director, and entities affiliated with Mr. Tangney and entities affiliated with InterWest Partners, Emergence Capital Partners, and Morgenthaler Ventures.

Limitation of Liability and Indemnification of Officers and Directors

Our amended and restated certificate of incorporation contains provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following:

•any breach of their duty of loyalty to our Company or our stockholders;

•any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

•any unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or

•any transaction from which they derived an improper personal benefit.

Any amendment to, or repeal of, these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to that amendment or repeal. If the Delaware General Corporation Law is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of our directors will be further limited to the greatest extent permitted by the Delaware General Corporation Law.

In addition, our amended and restated bylaws provide that we will indemnify, to the fullest extent permitted by law, any person who is or was a party or is threatened to be made a party to any action, suit or proceeding by reason of the fact that he or she is or was one of our directors or officers or is or was serving at our request as a director or officer of another corporation, partnership, joint venture, trust or other enterprise. Our amended and restated bylaws provide that we may indemnify to the fullest extent permitted by law any person who is or was a party or is threatened to be made a party to any action, suit or proceeding by reason of the fact that he or she is or was one of our employees or agents or is or was serving at our request as an employee or agent of another corporation, partnership, joint venture, trust or other enterprise. Our amended and restated bylaws also provide that we must advance expenses incurred by or on behalf of a director or officer in advance of the final disposition of any action or proceeding, subject to very limited exceptions.

Further, we have entered into indemnification agreements with each of our directors and executive officers that may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements require us, among other things, to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require us to advance all expenses incurred by the directors and executive officers in investigating or defending any such action, suit or

proceeding. We believe that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers.

The limitation of liability and indemnification provisions that are included in our amended and restated certificate of incorporation, amended and restated bylaws and in indemnification agreements that we enter into with our directors and executive officers may discourage stockholders from bringing a lawsuit against our directors and executive officers for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against our directors and executive officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder’s investment may be harmed to the extent that we pay the costs of settlement and damage awards against directors and executive officers as required by these indemnification provisions. At present, we are not aware of any pending litigation or proceeding involving any person who is or was one of our directors, officers, employees or other agents or is or was serving at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, for which indemnification is sought, and we are not aware of any threatened litigation that may result in claims for indemnification.

We maintain insurance policies under which, subject to the limitations of the policies, coverage is provided to our directors and executive officers against loss arising from claims made by reason of breach of fiduciary duty or other wrongful acts as a director or executive officer, including claims relating to public securities matters, and to us with respect to payments that may be made by us to these directors and executive officers pursuant to our indemnification obligations or otherwise as a matter of law.

Certain of our non-employee directors may, through their relationships with their employers, be insured and/or indemnified against certain liabilities incurred in their capacity as members of our board.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling our Company pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

Procedures for Approval of Related Party Transactions

Our audit committee charter provides that the audit committee has the primary responsibility for reviewing and approving or disapproving “related party transactions,” which are transactions between us and related persons in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and in which a related person has or will have a direct or indirect material interest. For purposes of this policy, a related person is defined as a director, executive officer, nominee for director or greater than 5% beneficial owner of our common stock, in each case since the beginning of the most recently completed year, and their immediate family members.

Certain of the transactions described above were entered into prior to the adoption of this policy. Accordingly, such transactions were approved by either the audit committee or the disinterested members of our board after making a determination that the transaction was executed on terms no less favorable than those that could have been obtained from an unrelated third party. Any related party transactions entered into after we adopted this policy were approved by our audit committee after making a determination that the transaction was executed on terms no less favorable than those that could have been obtained from an unrelated third party.

ADDITIONAL INFORMATION

Our board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the Annual Meeting, the persons appointed in the accompanying proxy intend to vote the shares represented thereby in accordance with their best judgment on such matters, under applicable laws.

Delinquent Section 16(a) Reports

Section 16(a) of the Exchange Act requires our directors and executive officers and persons who own more than 10% of our common stock, to file with the SEC initial reports of beneficial ownership and reports of changes in beneficial ownership. Officers, directors and greater than 10% stockholders are required by SEC regulations to furnish us with copies of all such reports.

To our knowledge, based solely on a review of the copies of such reports furnished to us and written representations that no other reports were required, we believe that all required reports were filed on a timely basis under Section 16(a) other than a Form 4 Amendment filed by Mr. Tangney on November 30, 2023, amending a prior Form 4 originally filed November 19, 2021 disclosing a transaction from November 10, 2021.

* * *

Final Proxy Card JPEG (2024 Annual Meeting)_Page_1.jpg

Final Proxy Card JPEG (2024 Annual Meeting)_Page_2.jpg

Get the next $DOCS alert in real time by email

Date	Price Target	Rating	Analyst
11/15/2024	$58.00	Neutral	Goldman
11/14/2024	$33.00 → $53.00	Underweight → Equal-Weight	Morgan Stanley
11/13/2024	$40.00 → $60.00	Buy → Hold	Canaccord Genuity
11/8/2024	$19.00 → $41.00	Underweight → Equal Weight	Wells Fargo
11/8/2024	$70.00	Sector Weight → Overweight	KeyBanc Capital Markets
10/15/2024	$35.00 → $52.00	Equal Weight → Overweight	Barclays
8/9/2024	$38.00	Hold → Buy	Needham
7/18/2024	$27.00 → $19.00	Equal Weight → Underweight	Wells Fargo

SEC Form DEF 14A filed by Doximity Inc.

Chat with this insight

Recent Analyst Ratings for $DOCS

$DOCS Leadership Updates

Live Leadership Updates

Mendaera Closes $73M Series B Financing to Scale Robotics and AI Across Mainstream Medical Procedures

Doximity Appoints Phoebe Yang to Its Board of Directors

$DOCS Large Ownership Changes

This live feed shows all institutional transactions in real time.

$DOCS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Amendment: SEC Form SC 13G/A filed by Doximity Inc.

SEC Form SC 13G filed by Doximity Inc.

SEC Form SC 13G filed by Doximity Inc.

Goldman initiated coverage on Doximity with a new price target

Doximity upgraded by Morgan Stanley with a new price target

Doximity downgraded by Canaccord Genuity with a new price target

$DOCS SEC Filings

SEC Form 10-Q filed by Doximity Inc.

Doximity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by Doximity Inc.

$DOCS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Bryson Anna covered exercise/tax liability with 5,120 shares, decreasing direct ownership by 2% to 299,386 units (SEC Form 4)

Chief Executive Officer Tangney Jeffrey covered exercise/tax liability with 21,087 shares, decreasing direct ownership by 0.83% to 2,530,497 units (SEC Form 4)

Chief Financial Officer Bryson Anna converted options into 100,000 shares and sold $5,842,248 worth of shares (100,000 units at $58.42) (SEC Form 4)

$DOCS Financials

Live finance-specific insights

$DOCS Market Insights

Live Market Insights

Doximity Announces Fiscal 2025 Second Quarter Financial Results

Doximity to Release Fiscal 2025 Second Quarter Results on November 7, 2024

Doximity Announces Fiscal 2025 First Quarter Financial Results

Doximity shares are trading lower after Wells Fargo downgraded the stock from Equal-Weight to Underweight and lowered its price target from $27 to $19.

Cracking The Code: Understanding Analyst Reviews For Doximity

Wells Fargo Downgrades Doximity to Underweight, Lowers Price Target to $19

$DOCS Press Releases

Fastest customizable press release news feed in the world

Doximity Announces Fiscal 2025 Second Quarter Financial Results

Doximity to Present at the Jefferies London Healthcare Conference

Doximity to Release Fiscal 2025 Second Quarter Results on November 7, 2024

Recent Analyst Ratings for
$DOCS

$DOCS
Leadership Updates

$DOCS
Large Ownership Changes

$DOCS
Analyst Ratings

$DOCS
SEC Filings

$DOCS
Insider Trading

$DOCS
Financials

$DOCS
Market Insights

$DOCS
Press Releases